calcipotriene profile

calcipotriene: a topical dermatologic for the treatment of moderate plaque psoriasis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

calcipotriol hydrate : A hydrate that is the monohydrate form of calcipotriol. It is used in combination with betamethasone dipropionate, a corticosteroid, for the topical treatment of plaque psoriasis in adult patients. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	49800068
CHEBI ID	90861
SCHEMBL ID	465450
MeSH ID	M0155262
PubMed CID	5288783
CHEMBL ID	1200666
CHEBI ID	50749
SCHEMBL ID	2853
MeSH ID	M0155262

Synonym
HY-10001A
calcipotriol (monohydrate)
calcipotriene
dovonex (tn)
calcipotriene hydrate
calcipotriol hydrate
calcipotriene monohydrate
D10198
calcipotriol hydrate (jan)
s7499tyy6g ,
unii-s7499tyy6g
CS-0812
calcipotriene hydrate component of taclonex
9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1.alpha.,3.beta.,5z,7e,22e,24s)-, monohydrate
taclonex component calcipotriene hydrate
calcipotriol monohydrate [who-dd]
calcipotriol hydrate [jan]
calcipotriene monohydrate [usp monograph]
calcipotriol monohydrate [ep monograph]
mc-903 hydrate
enstilar component calcipotriene hydrate
calcipotriene hydrate component of enstilar
calcipotriene hydrate [orange book]
CHEBI:90861
(1s,3r,5z,7e,22e,24s)-26,27-cyclo-9,10-secocholesta-5,7,10,22-tetraene-1,3,24-triol hydrate
SCHEMBL465450
AKOS025312514
calcipotriol hydrate, >=98% (hplc)
Q27162836
A902099
(1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(1r,2e,4s)-4-cyclopropyl-4-hydroxy-1-methyl-2-buten-1-yl]octahydro-7a-methyl-4h-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol monohydrate
MS-27664
(1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(e,2r,5s)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol;hydrate
calcipotriol (hydrate)
(1R,3S,Z)-5-(2-((1R,3AS,7AR,E)-1-((2R,5S,E)-5-CYCLOPROPYL-5-HYDROXYPENT-3-EN-2-YL)-7A-METHYLOCTAHYDRO-4H-INDEN-4-YLIDENE)ETHYLIDENE)-4-METHYLENECYCLOHEXANE-1,3-DIOL HYDRATE
EX-A4430A
LMST03020106
(22e)-(24s)-1alpha,24-dihydroxy-26,27-cyclo-22,23-didehydrovitamin d3 / (22e)-(24s)-1alpha,24-dihydroxy-26,27-cyclo-22,23-didehydrocholecalciferol / calcipotriol
(5z,7e,22e)-(1s,3r,24s)-26,27-cyclo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol
mc 903
calcipotriene [usan]
(5z,7e,22e,24s)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1alpha,3beta,24-triol
9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1alpha,3beta,5z,7e,22e)-
9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1alpha,3beta,5z,7e,22e,24s)-
ccris 7700
1,24(oh)2-22-ene-24-cyclopropyl d3
HY-10001
HMS3269P03
AB00698343-05
gtpl2778
stf-115469
divonex
mc-903
daivonex
bms-181161
u-0267
psorcutan
sorilux
dovonex
CHEBI:50749 ,
calcipotriol ,
MLS001424130
MLS000759467
smr000466353
DB02300
cpd000466353
calcipotriene (usp)
calcipotriol (jan)
D01125
NCGC00167465-01
mc903
HMS2051N11
HMS2089J08
pri-2201
CHEMBL1200666
calciptriol
calcipotriol anhydrous
(1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(e,2r,5s)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
dtxcid8026648
dtxsid0046648 ,
S3739
CCG-100949
pri 2201
unii-143nq3779b
calcipotriol [inn]
calcitrene
143nq3779b ,
bdbm50369964
EPITOPE ID:114242
1S19
CS-0387
AKOS015855239
calcipotriene [orange book]
calcipotriol [ep monograph]
calcipotriol [mart.]
calcipotriene [vandf]
calcipotriene [mi]
calcipotriol [who-dd]
calcipotriene [usp monograph]
calcipotriene [usp-rs]
calcipotriol [jan]
9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1.alpha.,3.beta.,5z,7e,22e,24s)-
NC00199
SCHEMBL2853
(1?,3?,5z,7e,22e,24s)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol
SR-01000762910-4
sr-01000762910
SR-01000762910-3
HMS3713K08
(1s,3r,5z,7e,14beta,17alpha,22e,24s)-26,27-cyclo-9,10-secocholesta-5,7,10,22-tetraene-1,3,24-triol
HMS3677D04
LWQQLNNNIPYSNX-UROSTWAQSA-N
HMS3413D04
Q155683
AMY2864
calcipotrienemc 903
EX-A4430
AS-56390
EN300-21702588
(1r,3s,5z)-5-{2-[(1r,3as,4e,7ar)-1-[(2r,3e,5s)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-octahydro-1h-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol
calcipotriene (usp-rs)
calcipotriolum
d05ax02
calsodore
calcipotriol (ep monograph)
(1s,3r,5z,7e,22e,24s)-26,27-cyclo-9,10-secocholesta-5,7,10,22-tetraene-1,3,24-triol
calcipotriolo
calcipotriene (usp monograph)
calcipotriol (mart.)

Excerpt	Reference	Relevance
"Topical application of up to 50 gm of calcipotriol ointment per week was found to be an effective and safe treatment of psoriasis vulgaris."	( Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. Bazex, JA; Beylot, C; Chevrant-Breton, J; Dubertret, L; Jurgensen, HJ; Kalis, B; Meynadier, J; Perussel, M; Souteyrand, P; Wallach, D, 1992)	0.28
"Short-term treatment with calcipotriol ointment (50 micrograms/g) used in amounts up to about 100 g/wk is moderately efficacious, well-tolerated, and safe in adult patients with various ichthyoses."	( Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study. Axelsen, MB; Esmann, J; Ibsen, HH; Kragballe, K; Sorensen, LH; Steijlen, PM; van de Kerkhof, PC, 1995)	0.29
" A safe and convenient new treatment modality would be of value to most patients with psoriasis."	( Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. Highton, A; Quell, J, 1995)	0.29
" Only minor treatment-related adverse events were observed."	( Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. Highton, A; Quell, J, 1995)	0.29
" The drug did not have any adverse effects on the postnatal development of the offspring such as differentiation, functional development, emotionality, motor ability, learning ability or reproductive performance."	( [Reproductive and developmental toxicity studies of calcipotriol (MC903): (4)--A perinatal and postnatal study in rats by subcutaneous administration]. Koike, Y; Konishi, R; Nagata, M; Ono, M; Shirakawa, K; Suzuki, T; Uchiyama, H, 1996)	0.29
" Patients were carefully questioned and observed at each visit for adverse events."	( Long-term effectiveness and safety of topical calcipotriene for psoriasis. Calcipotriene Study Group. Cullen, SI, 1996)	0.29
" Eight patients withdrew from the study (four defaulted, two unacceptable responses, two adverse events)."	( Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Cunliffe, WJ; Darley, CR; Downes, N; Green, CM; Hutchinson, PE; Klaber, MR, 1996)	0.29
" Therefore an effective and safe treatment modality is needed."	( A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. Park, SB; Suh, DH; Youn, JI, )	0.13
" There was no difference in the PASI, patient's and investigator's overall assessments and number of adverse events recorded by either group for both the treatment and follow-up phases."	( Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Bolduc, A; Gilbert, M; Lowson, D; Papp, K; Ramsay, CA; Schwartz, BE, 2000)	0.31
"Calcipotriol cream + twice weekly broad-band UVB phototherapy is an effective and safe antipsoriatric treatment, resulting in fewer UVB exposures, lower cumulative irradiance and a saving of time."	( Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Bolduc, A; Gilbert, M; Lowson, D; Papp, K; Ramsay, CA; Schwartz, BE, 2000)	0.31
" Safety data showed the frequency of adverse events to be less in the combined formulation groups than in both the calcipotriol group and the vehicle group."	( Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Chu, AC; Garcia-Diez, A; Guenther, L; Kragballe, K; Snellman, E; Springborg, J; Tegner, E; Van de Kerkhof, PC, 2002)	0.31
" Several clinical trials have demonstrated that calcitriol, the naturally occurring and hormonally active form of vitamin D3, is effective and safe at the dose of 3 microg g(-1) for the treatment of psoriasis affecting the trunk and limbs."	( Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Czernielewski, J; Dubertret, L; Humbert, P; Janin, A; Lahfa, M; Nicolas, JF; Ortonne, JP; Tonev, SD; Tsankov, N, 2003)	0.32
" Adverse events were more common in the calcipotriol group than in the clobetasol propionate shampoo group."	( Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. Acebes, LO; Arsonnaud, S; Caputo, R; de Waard-van der Spek, FB; Decroix, J; Figueiredo, A; Mrowietz, U; Poncet, M; Reygagne, P, 2005)	0.33
"The calcipotriol/betamethasone dipropionate two-compound product Dovobet/Daivobet/Taclonex(LEO Pharma A/S, Ballerup, Denmark) has been shown to be safe and effective in the treatment of psoriasis for up to 8 weeks."	( A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Austad, J; Barnes, L; Bibby, A; Cambazard, F; de la Brassinne, M; Fleming, C; Heikkilä, H; Jolliffe, D; Kragballe, K; Peyri, J; Svensson, A; Toole, J; Wozel, G, 2006)	0.33
"Treatment with the two-compound product for up to 52 weeks appears to be safe and well tolerated whether used on its own or alternating every 4 weeks with calcipotriol treatment."	( A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Austad, J; Barnes, L; Bibby, A; Cambazard, F; de la Brassinne, M; Fleming, C; Heikkilä, H; Jolliffe, D; Kragballe, K; Peyri, J; Svensson, A; Toole, J; Wozel, G, 2006)	0.33
"The calcipotriol/betamethasone dipropionate two-compound product is safe and effective in the short-term treatment of psoriasis."	( Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Austad, J; Barnes, L; Bibby, A; Cambazard, F; de la Brassinne, M; Fleming, C; Heikkilä, H; Kragballe, K; Peyri Rey, J; Svensson, A; Toole, J; Williams, Z; Wozel, G, 2006)	0.33
" Safety evaluations included adverse event reporting, cutaneous safety assessed by the investigator and cutaneous discomfort assessment by the subject (both on a 5-point scale from 0: none, to 4: very severe)."	( An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. Andres, P; Briantais, P; Chen, Z; Gu, J; Wang, B; Zhao, G; Zhu, X, 2007)	0.34
" Fourteen dermatological and treatment-related adverse events were reported with calcipotriol vs."	( An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. Andres, P; Briantais, P; Chen, Z; Gu, J; Wang, B; Zhao, G; Zhu, X, 2007)	0.34
" Both treatments were safe and well tolerated."	( Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. Andreassi, L; Ayala, F; Bongiorno, MR; Chimenti, S; Giannetti, A; Lisi, P; Martini, P; Peris, K; Peserico, A; Saraceno, R, 2007)	0.34
"Effective and safe products are needed for long-term management of scalp psoriasis."	( A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Bourcier, M; Cambazard, F; Clonier, F; Gupta, G; Kidson, P; Larsen, FG; Luger, TA; Shear, NH, 2008)	0.35
" Incidences of adverse events possibly associated with long-term corticosteroid use were low in both the two-compound (2."	( A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Bourcier, M; Cambazard, F; Clonier, F; Gupta, G; Kidson, P; Larsen, FG; Luger, TA; Shear, NH, 2008)	0.35
" Secondary efficacy outcomes and adverse events were also evaluated."	( Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Hoffmann, V; Kragballe, K; Nordin, P; Ortonne, JP; Segaert, S; Tan, J, 2009)	0.35
" Further evidence of the superiority of the two-compound scalp formulation over the scalp solution was demonstrated through greater improvements in clinical signs and fewer adverse events."	( Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Hoffmann, V; Kragballe, K; Nordin, P; Ortonne, JP; Segaert, S; Tan, J, 2009)	0.35
"High-potency topical corticosteroids are very effective for the treatment of psoriasis, but are associated with a number of cutaneous adverse effects."	( Calcitriol 3 microg/g ointment: an effective and safe addition to the armamentarium in topical psoriasis therapy. Abramovits, W, 2009)	0.35
" Adverse event incidences were similar between patients with and without prior anti-TNF therapy."	( Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. Chimenti, S; Gniadecki, R; Goldblum, O; Kupper, H; Ortonne, JP; Reich, K; Sprøgel, P; Thaçi, D; Unnebrink, K, 2011)	0.37
" No adverse effects related to the study, including skin irritation, were observed or reported."	( Evaluating the efficacy and safety of calcipotriene/betamethasone ointment occluded with a hydrogel patch: a 6-week bilaterally controlled, investigator-blinded trial. Bhutani, T; Busse, KL; Koo, J; Patel, T, 2011)	0.37
" Adverse events (AEs) were recorded throughout the study."	( Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. Bruce, S; Brundage, T; Feldman, SR; Grande, K; Kempers, S; Markowitz, O; Matheson, R; Wyres, M, 2012)	0.38
" Calcipotriene foam was safe with an overall incidence of AEs similar to those experienced in the vehicle foam group."	( Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. Bruce, S; Brundage, T; Feldman, SR; Grande, K; Kempers, S; Markowitz, O; Matheson, R; Wyres, M, 2012)	0.38
"005% foam was safe and effective for the treatment of mild to moderate plaque-type psoriasis for up to 8 weeks."	( Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. Bruce, S; Brundage, T; Feldman, SR; Grande, K; Kempers, S; Markowitz, O; Matheson, R; Wyres, M, 2012)	0.38
" Twenty-seven patients (35%) reported a total of 64 adverse events (AEs); most were mild (33/64) or moderate (22/64) in severity and there were no serious AEs."	( Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12-17 years of age. Debarre, JM; Gooderham, M; Goodfield, M; Keddy-Grant, J; Kurvits, M; Xu, Z, 2014)	0.4
"Narrow-band ultraviolet B (NB-UVB) is an effective and safe treatment for vitiligo."	( Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB-UVB vs. NB-UVB alone in the treatment of vitiligo: a 24-week prospective right-left comparative clinical trial. Kanwar, AJ; Khullar, G; Parsad, D; Singh, S, 2015)	0.42
" Calcipotriol produced mild local adverse effects."	( Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB-UVB vs. NB-UVB alone in the treatment of vitiligo: a 24-week prospective right-left comparative clinical trial. Kanwar, AJ; Khullar, G; Parsad, D; Singh, S, 2015)	0.42
" Sixteen patients (52%) experienced a total of 20 adverse events; 19 were considered unrelated to study treatment, 14 were mild, and none were serious or lesional or perilesional on the scalp."	( Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years. Eichenfield, LF; Ganslandt, C; Kurvits, M; Schlessinger, J, )	0.13
"Calcipotriol/betamethasone dipropionate combination in a non-alcoholic, lipophilic gel formulation (two-compound gel) has previously been demonstrated as a safe and effective treatment for scalp psoriasis in Caucasian, Hispanic/Latino, and Black/African American populations."	( Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population. Cui, P; Facy, P; Gao, T; Ge, M; Gu, J; Hao, F; Kurvits, M; Li, R; Ma, L; Sun, Q; Wang, G; Xu, J; Xu, Z; Yang, H; Yang, Q; Zheng, M, 2016)	0.43
" The two-compound gel was associated with fewer adverse drug reactions than calcipotriol scalp solution (18."	( Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population. Cui, P; Facy, P; Gao, T; Ge, M; Gu, J; Hao, F; Kurvits, M; Li, R; Ma, L; Sun, Q; Wang, G; Xu, J; Xu, Z; Yang, H; Yang, Q; Zheng, M, 2016)	0.43
" Safety was monitored by adverse events/calcium homeostasis."	( Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST). Bagel, J; Leonardi, C; Olesen, M; Pariser, D; Stein Gold, L; Xu, Z; Yamauchi, P; Østerdal, ML, 2015)	0.42
" Adverse drug reactions were reported in 10 Cal/BD foam patients (3."	( Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST). Bagel, J; Leonardi, C; Olesen, M; Pariser, D; Stein Gold, L; Xu, Z; Yamauchi, P; Østerdal, ML, 2015)	0.42
" The adverse effects (most commonly hyperpigmentation) were noted more frequently on the excimer-treated sides; however, they were well tolerated."	( Comparison of effectiveness and safety of excimer lamp vs topical calcipotriol-clobetasol propionate combination in the treatment of palmoplantar psoriasis. Bishnoi, A; Dogra, S; Narang, T; Thakur, A, 2018)	0.48
"Psoriasis is commonly treated with topical corticosteroids, oral cytotoxic drugs and biologic agents, which can be associated with significant adverse effects (AEs), high cost and response attenuation."	( Efficacy and safety of HAT1 compared with calcipotriol in the treatment of patients with mild to moderate chronic plaque psoriasis: results from an open-label randomized comparative pilot clinical study. Alex, P; Centola, M; Sutton, C; Sutton, L; Thomas, S; Williams, S; Yesudas, T, 2020)	0.56
" Safety response criteria included adverse drug reactions [ADRs; any adverse event (AE) possibly or probably related to treatment as determined by the investigator; a primary response criterion] and AEs (a secondary response criterion)."	( Safety and efficacy of topical, fixed-dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial. Eichenfield, LF; Kurvits, M; Liljedahl, M; Marcoux, D, 2020)	0.56
" Primary objectives included treatment-emergent adverse events (TEAEs) and systemic calcium levels in the overall population, and HPA-axis function, change in calcium excretion and the calcium:creatinine ratio in the HPA-axis cohort."	( Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial. Abramovits, W; Hoejen, MN; Liljedahl, M; Seyger, M; Teng, J, 2020)	0.56
" Cal/BD foam plus apremilast appeared to be safe and well tolerated."	( Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis. Kircik, LH; Schlesinger, TE; Tanghetti, E, 2020)	0.56
" Incidence of adverse drug reactions (ADRs) of any type and adverse events (AEs) of concern associated with long-term corticosteroid use on the scalp were evaluated."	( Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled Cao, S; Chen, K; Chen, Y; Cheng, H; Ding, Y; Fang, H; Han, X; He, L; He, Y; Huang, J; Li, M; Li, S; Li, W; Liu, L; Lu, Q; Lu, Y; Pan, W; Wang, J; Yan, G; Zhang, C; Zhang, J; Zheng, M; Zhu, W, 2020)	0.56
" There was no significant difference in treatment-emergent adverse events (TEAEs) associated with long-term topical corticosteroid use on the scalp (1."	( Comparison of safety and efficacy between calcipotriol plus betamethasone dipropionate gel and calcipotriol scalp solution as long-term treatment for scalp psoriasis in Chinese patients: a national, multicentre, prospective, randomized, active-controlled Cao, S; Chen, K; Chen, Y; Cheng, H; Ding, Y; Fang, H; Han, X; He, L; He, Y; Huang, J; Li, M; Li, S; Li, W; Liu, L; Lu, Q; Lu, Y; Pan, W; Wang, J; Yan, G; Zhang, C; Zhang, J; Zheng, M; Zhu, W, 2020)	0.56
" This superior efficacy was not associated with an increased frequency or severity of adverse events, and there was no evidence for dysregulation of the hypothalamic-pituitary-adrenal axis or calcium homeostasis."	( Efficacy and safety of fixed-dose combination calcipotriol/betamethasone dipropionate foam for the treatment of psoriasis. Paul, C; Romiti, R; Stein Gold, L, 2021)	0.62
" Efficacy was evaluated based on primary outcome indicators including skin lesion improvement and overall adverse reaction rate."	( Clinical efficacy and safety of using calcipotriol-betamethasone compounding agent for psoriasis treatment: a systematic review and meta-analysis. Ding, H; Dong, S; Feng, J; Li, N; Li, X; Ren, J; Sun, Z; Wang, H; Wang, S; Zhu, Q, 2022)	0.72
" There was no adverse drug reaction reported with a frequency of >1%, associated with the CAL/BDP PAD-cream."	( A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis. Augustin, M; Gold, LS; Green, LJ; Pinter, A; Praestegaard, M; Selmer, J, 2022)	0.72
" Smartphone app images documented adverse events and mild local skin reactions, particularly erythema (75%), laser-induced swelling (28%), and crusting (27%)."	( Investigating the efficacy and safety of calcipotriol/betamethasone dipropionate foam and laser microporation for psoriatic nail disease-A hybrid trial using a smartphone application, optical coherence tomography, and patient-reported outcome measures. Bourlioux, M; Fuchs, CSK; Haedersdal, M; Mandel, VD; Nissen, CV; Ortner, VK; Philipsen, PA; Skak, K; Zibert, JR, 2022)	0.72
" Calcipotriol did not cause adverse effects on cartilage or subchondral bone within a week, suggesting that it could be safely used in local treatment of arthritis."	( No adverse effects on periarticular tissue by intra-articular vitamin D analogue calcipotriol in a reduced-dose zymosan-induced arthritis model in rats. Finnilä, M; Huhtakangas, JA; Huovinen, J; Kauppinen, S; Laaksonen, S; Lehenkari, P; Lohela, J; Voipio, HM, 2023)	0.91
" Overall, nine mild non-serious treatment-emergent adverse effects related to all calcipotriol formulations were reported in four subjects, but all recovered at the follow-up visit."	( Efficacy and Safety of Water-Free Lipid Formulation System Containing Calcipotriol Against Psoriasis Vulgaris. Carlsson, A; Holmback, J; Rinwa, P, 2023)	0.91
" All adverse events were mild and deemed unrelated to treatment by the investigators."	( Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color. Alexis, A; Cices, A; Kaufman, B; Liu, J; Sanabria-Gonzalez, I, 2023)	0.91
"Cal/BD foam was safe and well tolerated in plaque psoriasis patients with skin of color."	( Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color. Alexis, A; Cices, A; Kaufman, B; Liu, J; Sanabria-Gonzalez, I, 2023)	0.91
" Adverse event rates were similar between the subgroup with skin types IV to VI and the total study population for all treatment arms."	( Efficacy, Convenience, and Safety of Calcipotriene-Betamethasone Dipropionate Cream in Skin of Color Patients With Plaque Psoriasis. Bhatia, N; Callender, VD; Curcio, A; Feldman, SR; Gorodokin, B; Kircik, L; Kontzias, CL; Tissera, KA, 2023)	0.91
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32

Excerpt	Reference	Relevance
" To elucidate this difference, the pharmacokinetic profiles after a single intravenous dose (50 micrograms/kg) of the two compounds to rats were compared."	( Calcipotriol (MC 903): pharmacokinetics in rats and biological activities of metabolites. A comparative study with 1,25(OH)2D3. Binderup, L; Kissmeyer, AM, 1991)	0.28

Excerpt	Reference	Relevance
" We used low-dose narrow-band UVB phototherapy, combined with balneotherapy, short-contact anthralin, liquor carbonis detergens and calcipotriol for treatment of psoriatic patients in our day care centre."	( Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and does not inhibit systemic T-cell activation. Bos, JD; de Rie, MA; Out, TA, 1998)	0.3
" Subsequently, this low-dose irradiation regimen was used in combination with topical medication in 26 psoriatic patients."	( Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and does not inhibit systemic T-cell activation. Bos, JD; de Rie, MA; Out, TA, 1998)	0.3
"Our data indicate that low-dose narrow-band UVB can be used successfully, in combination with topical treatment, in a day care setting to treat psoriatic patients."	( Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and does not inhibit systemic T-cell activation. Bos, JD; de Rie, MA; Out, TA, 1998)	0.3
"Calcipotriol has been combined with a number of systemic antipsoriatric treatments, improving efficacy or reducing the systemic treatment required."	( Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Bolduc, A; Gilbert, M; Lowson, D; Papp, K; Ramsay, CA; Schwartz, BE, 2000)	0.31
"To assess the efficacy and safety of calcipotriol cream (50 microg/g) combined with twice weekly broad-band UVB and to determine if this treatment would require fewer UVB treatments and lower cumulative UVB irradiance when compared to a standard 3 times weekly broad-band UVB regime in patients with extensive psoriasis."	( Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Bolduc, A; Gilbert, M; Lowson, D; Papp, K; Ramsay, CA; Schwartz, BE, 2000)	0.31
" Remarkably, vitiligo lesions treated with calcipotriol initially showed delayed repigmentation compared with control areas; however, there was no therapeutic difference between calcipotriol and placebo, both in combination with UVB311 nm, by the end of the study."	( Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Bröcker, EB; Hamm, H; Hartmann, A; Hofmann, UB; Lurz, C, 2005)	0.33
" In this randomized and comparative study, we investigated the safety and efficacy of narrow band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of generalized vitiligo."	( Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. Arca, E; Erbil, AH; Koç, E; Kurumlu, Z; Sezer, E; Taştan, HB, 2006)	0.33
" For this photo case presentation, Dovobet was used once daily in combination with UVB phototherapy 3 times a week."	( Calcipotriol (Dovobet) ointment in combination with UVB therapy for psoriasis treatment. Rogers, C, 2006)	0.33
"Treatment of plaque-type psoriasis with laser in combination with topical treatment is a safe and effective therapy."	( Treatment of plaque-type psoriasis with the 308 nm excimer laser in combination with dithranol or calcipotriol. Bodendorf, MO; Grunewald, S; Kauer, F; Paasch, U; Rogalski, C; Schetschorke, M; Simon, JC, 2012)	0.38
"This study aimed to compare the efficacy of targeted microphototherapy alone and in combination with psoralen or calcipotriol in the treatment of plaque-type psoriasis."	( Efficacy and safety of non-laser, targeted UVB phototherapy alone and in combination with psoralen gel or calcipotriol ointment in the treatment of localized, chronic, plaque-type psoriasis. Arca, E; Köse, O; Ozkan, I; Ozmen, I, 2012)	0.38
"Thirty individuals, affected by plaque-type psoriasis, were treated with targeted narrowband UVB phototherapy alone (Group 1), in combination with psoralen gel (Group 2), or in combination with calcipotriol ointment (Group 3) three times per week based on predetermined minimal erythema doses for 10 weeks."	( Efficacy and safety of non-laser, targeted UVB phototherapy alone and in combination with psoralen gel or calcipotriol ointment in the treatment of localized, chronic, plaque-type psoriasis. Arca, E; Köse, O; Ozkan, I; Ozmen, I, 2012)	0.38
"005%) in combination with NB-UVB vs."	( Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB-UVB vs. NB-UVB alone in the treatment of vitiligo: a 24-week prospective right-left comparative clinical trial. Kanwar, AJ; Khullar, G; Parsad, D; Singh, S, 2015)	0.42
" Larger, randomized placebo-controlled trials are required to determine whether addition of calcipotriol has any utility when administered with NB-UVB in the treatment of vitiligo."	( Comparison of efficacy and safety profile of topical calcipotriol ointment in combination with NB-UVB vs. NB-UVB alone in the treatment of vitiligo: a 24-week prospective right-left comparative clinical trial. Kanwar, AJ; Khullar, G; Parsad, D; Singh, S, 2015)	0.42
"The results of our study show that in the treatment of plaque-type psoriasis, topical calcipotriol combined with Spa Rusanda balineotherapy is more effective than topical calcipotriol alone."	( Effects of Rusanda Spa balneotherapy combined with calcipotriol on plaque psoriasis. Golusin, Z; Jovanović, M; Magda, N; Matić, M; Petrović, A; Stojanović, S, 2015)	0.42
" Here, we investigated the efficacy of calcipotriol, a topical TSLP inducer, in combination with 5-fluorouracil (5-FU) as an immunotherapy for actinic keratosis."	( Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. Cornelius, LA; Cunningham, TJ; Demehri, S; Eliane, JP; Kopan, R; Manivasagam, S; Mirzaalian, H; Saavedra, AP; Schaffer, A; Tabacchi, M; Tuchayi, SM; Turkoz, A; Wallendorf, M, 2017)	0.46
"005% calcipotriol ointment combined with 5% 5-FU cream were compared with Vaseline plus 5-FU for the field treatment of actinic keratosis in a randomized, double-blind clinical trial involving 131 participants."	( Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. Cornelius, LA; Cunningham, TJ; Demehri, S; Eliane, JP; Kopan, R; Manivasagam, S; Mirzaalian, H; Saavedra, AP; Schaffer, A; Tabacchi, M; Tuchayi, SM; Turkoz, A; Wallendorf, M, 2017)	0.46
" The objective of this open label, intraindividual, left right study was to compare two different vitamin D analogues, calcipotriol and tacalcitol, in combination with NBUVB phototherapy in chronic stable plaque psoriasis."	( Comparative evaluation of efficacy and safety of calcipotriol versus tacalcitol ointment, both in combination with NBUVB phototherapy in the treatment of stable plaque psoriasis. Aggarwal, K; Dua, I; Jain, VK, 2017)	0.46
" This pilot study assesses the effect of twice-weekly maintenance doses of Cal/BD foam after 4 weeks of standard once-daily treatment in combination with apremilast."	( The Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast. Kircik, L; Ozyurekoglu, E, 2022)	0.72
" The objective of this open label intraindividual, left right study was to compare two different vitamin D analogues, calcipotriol and calcitriol, in combination with NBUVB phototherapy in psoriasis."	( Comparative evaluation of efficacy and safety of calcipotriol versus calcitriol ointment, both in combination with narrow-band ultraviolet B phototherapy in the treatment of stable plaque psoriasis. Aggarwal, K; Chakraborty, D, 2023)	0.91

Excerpt	Reference	Relevance
" The differential therapeutic effects in the epidermal and dermal skin compartments may be due to a reduced bioavailability of calcipotriol in the dermal compartment."	( Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. Bahmer, FA; Baum, HP; Kerber, A; Müller, SM; Reichrath, J, 1997)	0.3
" Such a formulation may provide convenience and enhanced activity compared with separate applications, but it is essential that the biological activity and bioavailability of either active agent is not adversely affected by the other component."	( Bioavailability of betamethasone dipropionate when combined with calcipotriol. Traulsen, J, 2004)	0.32
"His study was designed to determine whether the bioavailability of the corticosteroid component of Daivobet was equivalent to that in a corticosteroid-only formulation (Diprosone, Schering-Plough Laboratories, France)."	( Bioavailability of betamethasone dipropionate when combined with calcipotriol. Traulsen, J, 2004)	0.32
" When applied, Cal/BD foam forms a supersaturated solution on the skin, increasing the penetration and bioavailability of Cal and BD."	( Early efficacy and safety data with fixed-dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency. Iversen, L; Koo, J; Tada, Y, 2021)	0.62

Excerpt	Relevance	Reference
" Serum from MC903 or 1,25(OH)2D3 dosed rats (i."	( Calcipotriol (MC 903): pharmacokinetics in rats and biological activities of metabolites. A comparative study with 1,25(OH)2D3. Binderup, L; Kissmeyer, AM, 1991)	0.28
"We report four cases of chronic plaque psoriasis that developed in patients who used UV-B phototherapy for a substantial period without ill effects and in whom photosensitivity reactions within psoriatic plaques developed after calcipotriene ointment was added, without changes in their UV-B dosage or frequency of treatment."	( Photosensitivity associated with combined UV-B and calcipotriene therapy. McKenna, KE; Stern, RS, 1995)	0.29
"Twice-daily dosing of calcipotriene was compared with its vehicle, for up to 8 weeks, in a double-blind study of 277 patients at 10 study centers in the United States."	( Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. Highton, A; Quell, J, 1995)	0.29
" No changes in parameters of reproductive performance were seen in any dosed groups."	( [Reproductive and developmental toxicity studies of calcipotriol (MC903): (1)--A fertility study in rats by subcutaneous administration]. Koike, Y; Konishi, R; Nagata, M; Ono, M; Shirakawa, K; Suzuki, T; Uchiyama, H, 1996)	0.29
" A dose-response analysis showed that a 10(-6) M concentration of this vitamin consistently induced a maximal accumulation of 7-fold over the control cells."	( Growth inhibition of human breast cancer cells by 1,25-dihydroxyvitamin D3 is accompanied by induction of apolipoprotein D expression. Alvarez, S; Binderup, L; López-Boado, YS; López-Otín, C; Puente, XS; Tolivia, J, 1997)	0.3
"These results underline the usefulness of the association of calcipotriol and cyclosporine in order to decrease the total dosage of cyclosporine."	( Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. Kokelj, F; Plozzer, C; Torsello, P, 1998)	0.3
" The objective of this study was to evaluate key measures of calcium metabolism in patients with psoriasis under supervised dosing conditions in a vehicle-controlled study."	( Evaluating the safety of calcipotriene 30 g per day in patients with psoriasis: a parallel group, vehicle-controlled study. Blum, R; Epinette, WW; Schwartzel, E; Siskin, S, 1998)	0.3
" The mean number of sessions and the cumulative UVA dosage for initial and complete repigmentation were calculated."	( Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Alpsoy, E; Cetin, L; Ermis, O; Yilmaz, E, 2001)	0.31
" Furthermore, in separate trials, calcipotriol combination therapy reduced the dosage of acitretin required to achieve clearance of psoriasis and the duration of PUVA and dosage of UVA phototherapy, potentially improving the benefit/risk ratio for these other antipsoriatic treatments."	( Calcipotriol ointment. A review of its use in the management of psoriasis. Dunn, CJ; Goa, KL; Scott, LJ, 2001)	0.31
" In addition, calcipotriol ointment proved beneficial in combination with other topical, phototherapy or systemic antipsoriatic treatments, reducing the dosage and/or duration of some of these treatments and potentially improving their benefit/risk ratio."	( Calcipotriol ointment. A review of its use in the management of psoriasis. Dunn, CJ; Goa, KL; Scott, LJ, 2001)	0.31
" Group A received FAE tablets (Fumaderm) with an increasing daily dosage from 105 to 1,075 mg + ointment vehicle."	( Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Altmeyer, P; Christophers, E; Gollnick, H; Kaufmann, R; Pavel, S; Ring, J; Ziegler, J, 2002)	0.31
"Little attention is given to accurate dosage of topical medication which is a potential source of side-effects and treatment failure."	( The importance of accurate dosage of topical agents: a method of estimating involved area and application to calcipotriol treatment failures. Hutchinson, PE; Osborne, JE, 2002)	0.31
" Three controlled clinical trials have demonstrated that the addition of calcipotriene ointment to systemic antipsoriatic treatment with MTX, acitretin, and cyclosporine increases the therapeutic efficacy compared with systemic therapy alone and minimizes side effects by either reducing the dosage or duration of treatment."	( Vitamin D and systemic therapy. van de Kerkhof, P, 2002)	0.31
" Group B included 33 patients treated with the same cyclosporin dosage plus, for the same time, topical application of calcipotriol cream twice a day."	( Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol. Amerio, P; Cerritelli, L; Feliciani, C; Forleo, P; Proietto, G; Tulli, A; Zampetti, A, )	0.13
" This combination not only provides earlier pigmentation with lower total UVB dosage and less adverse UVB effects, but also reduces the duration and cost of treatment as well."	( Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. Aydin, F; Canturk, MT; Goktas, EO; Senturk, N; Turanli, AY, 2006)	0.33
" In addition to screening potential antipsoriatic substances, the PPT can help answer other questions (frequency of use, dose-response relationship)."	( [Is the psoriasis plaque test still relevant in the age of biologicals?]. Wozel, G, 2006)	0.33
" A dose-response trend existed for increasing concentrations of nicotinamide, but it was not significant."	( Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. Andrashko, Y; Even-Chen, Z; Gottlieb, A; Lebwohl, M; Levine, D; Lipets, I; Pritulo, OA; Svyatenko, TV, 2010)	0.36
"The relatively small patient numbers, relatively high placebo effect, and maximum in-life portion of only 12 weeks of dosing are weaknesses of the study."	( Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis. Andrashko, Y; Even-Chen, Z; Gottlieb, A; Lebwohl, M; Levine, D; Lipets, I; Pritulo, OA; Svyatenko, TV, 2010)	0.36
"Etanercept is approved for the treatment of plaque psoriasis at a subcutaneous (SC) dosage of 50 mg twice-weekly for three months, followed by 50 mg SC once-weekly thereafter."	( Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial. Kircik, LH, 2011)	0.37
" Liposomes can enhance the delivery of drugs into the skin, but a major challenge for the development of dosage forms containing liposomes is to maintain the colloidal stability in the formulation."	( Calcipotriol delivery into the skin with PEGylated liposomes. Basse, LH; Foged, C; Frokjaer, S; Hansen, J; Jorgensen, L; Knudsen, NØ; Rønholt, S; Salte, RD; Thormann, T, 2012)	0.38
"Two chromatographic methods were developed, optimized and validated for simultaneous determination of calcipotriol monohydrate (CPM) and betamethasone dipropionate (BMD) in the presence of two dosage form additives named; butylated hydroxytoluene (BHT) and alpha-tocopherol (TOCO)."	( Validated Chromatographic Methods for Simultaneous Determination of Calcipotriol Monohydrate and Betamethasone Dipropionate in the Presence of Two Dosage Form Additives. El-Mosallamy, SS; El-Zeany, BA; Hassan, NY; Merey, HA, 2019)	0.51
" Improvements in disease severity outcomes were maintained after reducing Cal/BD dosing frequency."	( Adjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab. Bagel, J; Nelson, E, 2022)	0.72
" Twice-weekly maintenance application of topical Cal/BD aerosolized foam has recently been shown to prolong time to remission and is associated with fewer relapses in patients initially treated with standard dosing of the formulation."	( The Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast. Kircik, L; Ozyurekoglu, E, 2022)	0.72
" A water-free lipid-based formulation system has been developed to improve dosage and cosmetic properties along with patient compliance."	( Efficacy and Safety of Water-Free Lipid Formulation System Containing Calcipotriol Against Psoriasis Vulgaris. Carlsson, A; Holmback, J; Rinwa, P, 2023)	0.91

Role	Description
antipsoriatic	A drug used to treat psoriasis.
antipsoriatic	A drug used to treat psoriasis.
drug allergen	Any drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
hydrate	An addition compound that contains water in weak chemical combination with another compound.
hydroxy seco-steroid
seco-cholestane
cyclopropanes	Cyclopropane and its derivatives formed by substitution.
secondary alcohol	A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
triol	A chemical compound containing three hydroxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
USP1 protein, partial	Homo sapiens (human)	Potency	63.0957	0.0316	37.5844	354.8130	AID504865
geminin	Homo sapiens (human)	Potency	33.4983	0.0046	11.3741	33.4983	AID624296
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	10.1815	0.0056	12.3677	36.1254	AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Vitamin D3 receptor	Homo sapiens (human)	Kd	0.0003	0.0001	2.4626	9.5200	AID217167
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of DNA-templated transcription	Vitamin D3 receptor	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Vitamin D3 receptor	Homo sapiens (human)
cell morphogenesis	Vitamin D3 receptor	Homo sapiens (human)
skeletal system development	Vitamin D3 receptor	Homo sapiens (human)
calcium ion transport	Vitamin D3 receptor	Homo sapiens (human)
intracellular calcium ion homeostasis	Vitamin D3 receptor	Homo sapiens (human)
lactation	Vitamin D3 receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of gene expression	Vitamin D3 receptor	Homo sapiens (human)
negative regulation of keratinocyte proliferation	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of vitamin D 24-hydroxylase activity	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of bone mineralization	Vitamin D3 receptor	Homo sapiens (human)
phosphate ion transmembrane transport	Vitamin D3 receptor	Homo sapiens (human)
bile acid signaling pathway	Vitamin D3 receptor	Homo sapiens (human)
mRNA transcription by RNA polymerase II	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Vitamin D3 receptor	Homo sapiens (human)
decidualization	Vitamin D3 receptor	Homo sapiens (human)
intestinal absorption	Vitamin D3 receptor	Homo sapiens (human)
apoptotic process involved in mammary gland involution	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of apoptotic process involved in mammary gland involution	Vitamin D3 receptor	Homo sapiens (human)
regulation of calcidiol 1-monooxygenase activity	Vitamin D3 receptor	Homo sapiens (human)
mammary gland branching involved in pregnancy	Vitamin D3 receptor	Homo sapiens (human)
vitamin D receptor signaling pathway	Vitamin D3 receptor	Homo sapiens (human)
positive regulation of vitamin D receptor signaling pathway	Vitamin D3 receptor	Homo sapiens (human)
response to bile acid	Vitamin D3 receptor	Homo sapiens (human)
multicellular organism development	Vitamin D3 receptor	Homo sapiens (human)
cell differentiation	Vitamin D3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
DNA-binding transcription factor activity	Vitamin D3 receptor	Homo sapiens (human)
vitamin D response element binding	Vitamin D3 receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Vitamin D3 receptor	Homo sapiens (human)
DNA binding	Vitamin D3 receptor	Homo sapiens (human)
nuclear receptor activity	Vitamin D3 receptor	Homo sapiens (human)
protein binding	Vitamin D3 receptor	Homo sapiens (human)
zinc ion binding	Vitamin D3 receptor	Homo sapiens (human)
bile acid nuclear receptor activity	Vitamin D3 receptor	Homo sapiens (human)
nuclear retinoid X receptor binding	Vitamin D3 receptor	Homo sapiens (human)
calcitriol binding	Vitamin D3 receptor	Homo sapiens (human)
lithocholic acid binding	Vitamin D3 receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Vitamin D3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Vitamin D3 receptor	Homo sapiens (human)
nucleus	Vitamin D3 receptor	Homo sapiens (human)
nucleoplasm	Vitamin D3 receptor	Homo sapiens (human)
cytosol	Vitamin D3 receptor	Homo sapiens (human)
RNA polymerase II transcription regulator complex	Vitamin D3 receptor	Homo sapiens (human)
chromatin	Vitamin D3 receptor	Homo sapiens (human)
receptor complex	Vitamin D3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1613156	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 3.80%)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1613157	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.61%)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1613162	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 12.04%)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer.
AID1423172	Hepatoprotective activity against CCL4-induced liver damage in C57BL/6J mouse assessed as reduction in serum ALT levels at 20 ug/kg, po administered 5 times a week via gavage measured at 72 hrs post final CCl4 injection	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Design, Synthesis, and Antifibrosis Activity in Liver of Nonsecosteroidal Vitamin D Receptor Agonists with Phenyl-pyrrolyl Pentane Skeleton.
AID1613159	Induction of apoptosis in human MCF7 cells assessed as viable cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 94.3%)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer.
AID1353234	Transactivation of VDR (unknown origin) expressed in HEK293 cells harboring pENTER-CMV-human RXRalpha at 10'-8M to 10'-6M after 24 hrs by luciferase reporter gene assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis and biological evaluation of non-secosteriodal vitamin D receptor ligand bearing double side chain for the treatment of chronic pancreatitis.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1353235	Antifibrotic activity against TGFbeta1 stimulated rat LTC-14 cells assessed as inhibition of collagen 1 synthesis at 0.5 uM after 24 hrs by ELISA relative to calcipotriol	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis and biological evaluation of non-secosteriodal vitamin D receptor ligand bearing double side chain for the treatment of chronic pancreatitis.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID217167	Binding affinity to VDR receptor	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	New dermatological agents for the treatment of psoriasis.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1353231	Toxicity in caerulein induced chronic pancreatic C57BL/6J mouse model assessed as serum calcium levels at 0.5 mg/kg, po administered via gavage treated for 5 times per week measured after 3 days (Rvb = 0.25 umol/ml)	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis and biological evaluation of non-secosteriodal vitamin D receptor ligand bearing double side chain for the treatment of chronic pancreatitis.
AID1423169	Antifibrotic activity in C57BL/6J mouse model of CCl4-induced liver fibrosis assessed as reduction in hydroxyproline levels in liver at 20 ug/kg, po administered 5 times a week via gavage measured at 72 hrs post final CCl4 injection	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Design, Synthesis, and Antifibrosis Activity in Liver of Nonsecosteroidal Vitamin D Receptor Agonists with Phenyl-pyrrolyl Pentane Skeleton.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID216993	Binding of compound towards human Vitamin D3 receptor was determined in vitro	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor
AID1353252	Toxicity in caerulein induced chronic pancreatic C57BL/6J mouse model assessed as reduction in body weight at 0.5 mg/kg, po administered via gavage treated for 5 times per week measured after 3 days	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis and biological evaluation of non-secosteriodal vitamin D receptor ligand bearing double side chain for the treatment of chronic pancreatitis.
AID89329	Inhibition of growth of human keratinocytes	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	New dermatological agents for the treatment of psoriasis.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1423157	Binding affinity to VDR ligand binding domain (unknown origin) at 100 nM by fluorescence polarization assay relative to calcipotriol	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Design, Synthesis, and Antifibrosis Activity in Liver of Nonsecosteroidal Vitamin D Receptor Agonists with Phenyl-pyrrolyl Pentane Skeleton.
AID1353239	Antifibrotic activity against TGFbeta1 stimulated rat LTC-14 cells assessed as inhibition of alpha-SMA mRNA expression at 500 nM after 24 hrs by RT-qPCR analysis	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis and biological evaluation of non-secosteriodal vitamin D receptor ligand bearing double side chain for the treatment of chronic pancreatitis.
AID1353236	Antifibrotic activity against TGFbeta1 stimulated rat LTC-14 cells assessed as inhibition of collagen 1 level at 500 nM after 24 hrs by Western blot	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis and biological evaluation of non-secosteriodal vitamin D receptor ligand bearing double side chain for the treatment of chronic pancreatitis.
AID1613163	Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 31.32%)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer.
AID1423173	Hepatoprotective activity against CCL4-induced liver damage in C57BL/6J mouse assessed as reduction in serum TBA levels at 20 ug/kg, po administered 5 times a week via gavage measured at 72 hrs post final CCl4 injection	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Design, Synthesis, and Antifibrosis Activity in Liver of Nonsecosteroidal Vitamin D Receptor Agonists with Phenyl-pyrrolyl Pentane Skeleton.
AID1353232	Inhibition of fluoromone VDR red binding to human VDR LBD expressed in insect cells at 1 uM by fluorescent polarization assay relative to 1,25(OH)2D3	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis and biological evaluation of non-secosteriodal vitamin D receptor ligand bearing double side chain for the treatment of chronic pancreatitis.
AID1353238	Antifibrotic activity against TGFbeta1 stimulated rat LTC-14 cells assessed as inhibition of collagen 1 alpha 1 mRNA expression at 500 nM after 24 hrs by RT-qPCR analysis	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis and biological evaluation of non-secosteriodal vitamin D receptor ligand bearing double side chain for the treatment of chronic pancreatitis.
AID1423158	Agonist activity at VDR in human LX2 cells assessed as inhibition of TGFbeta1-induced collagen-1 synthesis at 100 nM after 24 hrs by ELISA relative to calcipotriol	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Design, Synthesis, and Antifibrosis Activity in Liver of Nonsecosteroidal Vitamin D Receptor Agonists with Phenyl-pyrrolyl Pentane Skeleton.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1613158	Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 1 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.29%)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1353237	Antifibrotic activity against TGFbeta1 stimulated rat LTC-14 cells assessed as inhibition of alpha-SMA level at 500 nM after 24 hrs by Western blot	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	Design, synthesis and biological evaluation of non-secosteriodal vitamin D receptor ligand bearing double side chain for the treatment of chronic pancreatitis.
AID1423171	Hepatoprotective activity against CCL4-induced liver damage in C57BL/6J mouse assessed as reduction in serum AST levels at 20 ug/kg, po administered 5 times a week via gavage measured at 72 hrs post final CCl4 injection	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Design, Synthesis, and Antifibrosis Activity in Liver of Nonsecosteroidal Vitamin D Receptor Agonists with Phenyl-pyrrolyl Pentane Skeleton.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID216996	Effective concentration required for inhibition of Vitamin D3 receptor; No data	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor
AID1613161	Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometric analysis (Rvb = 56.64%)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1902983	Toxicity in IMQ-induced BALB/c psoriasis mouse model assessed as body weight lossas at 0.05% ointment, TOP daily and measured after 4 days	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.
AID1423163	Transactivation of VDR in human LX2 cells assessed as inhibition of TGFbeta1-induced COL1A1 mRNA expression at 100 nM after 24 hrs by Q-PCR analysis	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Design, Synthesis, and Antifibrosis Activity in Liver of Nonsecosteroidal Vitamin D Receptor Agonists with Phenyl-pyrrolyl Pentane Skeleton.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	New dermatological agents for the treatment of psoriasis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	7 (0.66)	18.7374
1990's	305 (28.69)	18.2507
2000's	313 (29.44)	29.6817
2010's	289 (27.19)	24.3611
2020's	149 (14.02)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	338 (30.29%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	160 (14.34%)	6.00%
Reviews	1 (10.00%)	6.00%
Case Studies	167 (14.96%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	8 (0.72%)	0.25%
Observational	0 (0.00%)	0.25%
Other	443 (39.70%)	84.16%
Other	9 (90.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (121)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
[NCT02533973]	Phase 4	951 participants (Actual)	Interventional	2015-09-30	Completed
[NCT01105286]	Phase 1	24 participants (Actual)	Interventional	2010-04-30	Completed
A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoriasis Vulgaris. [NCT01297166]	Phase 1	25 participants (Actual)	Interventional	2011-02-28	Completed
A Phase 2a Trial Evaluating the Anti-psoriatic Effect of LP0113 Aerosol Spray Compared With Its Vehicle and With Daivobet® Gel, LEO 90100 Aerosol Foam, Betamethasone Dipropionate Aerosol Spray and Calcipotriol Aerosol Spray in the Treatment of Psoriasis V [NCT02416258]	Phase 2	50 participants (Actual)	Interventional	2015-04-30	Completed
An Investigator Initiated Study Evaluating the Efficacy and Tolerability of Enstilar Foam (Calcipotriene and Betamethasone Dipropionate) in Patients With Nail Psoriasis [NCT04227288]	Phase 4	3 participants (Actual)	Interventional	2021-11-01	Completed
Study Role of the Local Treatments on the Microbiome Modulation in the Psoriatic Skin. Study Monocentric, Interventional, Randomized and Single-blind [NCT03584360]	Phase 2	30 participants (Actual)	Interventional	2018-09-24	Completed
Phase II Study of a Non-Steroidal Novel Treatment for Scalp Psoriasis [NCT01368887]	Phase 2	160 participants (Anticipated)	Interventional	2013-04-30	Suspended(stopped due to Sponsor seeking additional financial support before starting the study)
A Phase II Multicenter Randomized Double-blind Comparator-Controlled Trial of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis [NCT03848806]	Phase 2	174 participants (Actual)	Interventional	2016-02-29	Completed
A Multicenter, Open-label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005%, in Pediatric Subjects (Ages 2 to 11 Years) With Plaque Psoriasis [NCT01582932]	Phase 1	36 participants (Actual)	Interventional	2013-04-30	Completed
Calcipotriol Plus 5-Fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients [NCT04642287]	Phase 2	64 participants (Anticipated)	Interventional	2026-01-31	Not yet recruiting
Calcipotriol Plus 5-Flourouracil Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients [NCT04329221]	Phase 2	62 participants (Anticipated)	Interventional	2026-01-01	Not yet recruiting
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, VEHICLE AND ACTIVE COMPARATOR-CONTROLLED, PSORIASIS PLAQUE TEST STUDY TO ASSESS SAFETY, TOLERABILITY, AND PSORIATIC SKIN INFILTRATE THICKNESS FOLLOWING REPEATED, TOPICAL DOSES OF PF-06763809 SOLUTION IN SUBJECTS WITH M [NCT03469336]	Phase 1	18 participants (Actual)	Interventional	2018-04-24	Completed
[NCT01301157]	Phase 2	294 participants (Actual)	Interventional	2011-02-28	Completed
Phase I, Single-center, Randomized, Controlled Trial to Evaluate the Antipsoriatic Efficacy of Calcipotriol in Novel Formulations Compared to Marketed Calcipotriol Products and Evaluation of Their Cutaneous Safety in a Psoriasis Plaque Test [NCT05488990]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2013-03-25	Completed
Evaluation of the Effect of Topical Calcipotriol Versus Platelet-Rich Plasma Versus Combined of Both on Serum Adiponectin Level in Alopecia Areata [NCT05954104]		80 participants (Actual)	Interventional	2023-07-01	Completed
A Phase II Study of the Dose-Effect of COL-121 Ointment in Patients With Plaque-Type Psoriasis [NCT00625326]	Phase 2	321 participants (Actual)	Interventional	2008-01-31	Completed
An Irritation Study With New Calcipotriol Ointment Formulations in Healthy Subjects [NCT01105234]	Phase 1	24 participants (Actual)	Interventional	2010-04-30	Completed
Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study Comparing Taro Product to RLD and Both Active Treatments to a Placebo Control in the Treatment of Scalp Psoriasis [NCT03880357]	Phase 1	485 participants (Actual)	Interventional	2018-10-22	Completed
Topical Calcipotriol Versus Narrowband Ultraviolet B in Treatment of Alopecia Areata: A Randomized Controlled Trial [NCT03847441]		60 participants (Actual)	Interventional	2017-10-01	Completed
Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis [NCT03441789]	Phase 4	28 participants (Actual)	Interventional	2017-09-18	Completed
A 28-day, Double-blind, Randomized, Reference-controlled Open Psoriasis Plaque Test for Within Subject Comparison of Efficacy and Safety of Mapracorat 0.1% Ointment and 4 Reference Products in Symptomatic Volunteers With Stable Plaque-type Psoriasis [NCT03399526]	Phase 1	24 participants (Actual)	Interventional	2013-02-11	Completed
A Phase 1b, Randomised, Controlled, Assessor-blinded Proof of Principle Trial to Assess Safety, Tolerability and Pharmacodynamics Effects of Microarray Patches Containing Calcipotriol/Betamethasone Dipropionate in Descaled Skin of Adults With Chronic Plaq [NCT03898583]	Phase 1	15 participants (Actual)	Interventional	2019-04-15	Completed
Real-life Evaluation of an Applicator, as a New Mode of Administration of Daivobet® Gel, on Adherence to Treatment and SAtisfaction of Patients With PSOriasis [NCT02856542]		1,560 participants (Actual)	Observational	2016-05-23	Completed
A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Syst [NCT00574249]	Phase 3	730 participants (Actual)	Interventional	2007-11-30	Completed
An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects [NCT03448081]	Phase 2	73 participants (Actual)	Interventional	2018-02-12	Completed
Multi-center,Single Blind, Parallel-Controlled Study of the Efficacy and Safety of Calcipotriol Betamethasone Ointment Plus Calcipotriol Ointment in Sequential Therapy to Psoriasis Vulgaris [NCT02191007]		230 participants (Actual)	Interventional	2013-11-30	Completed
Combination of 5-Fluorouracil and Calcipotriene in the Treatment of Superficial Basal Cell Carcinomas and Squamous Cell Carcinomas in Situ [NCT05381597]	Phase 2/Phase 3	200 participants (Anticipated)	Interventional	2022-10-15	Recruiting
Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Patients With Moderate to Severe Psoriasis [NCT04275024]		8 participants (Actual)	Interventional	2020-04-01	Completed
Efficacy and Safety of Expanded Allogeneic Adipose-derived Mesenchymal Stem Cells Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis [NCT03392311]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2019-07-23	Completed
A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005%, Applied Under Maximal-Use Conditions in Adolescent Subjects (Ages 12 to 16 Years) With Plaque Psoriasis [NCT01563068]	Phase 1	18 participants (Actual)	Interventional	2012-04-30	Completed
A Proof of Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Topical Administrations of BFH772 in Patients With Psoriasis. [NCT00987870]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2009-09-30	Completed
A Psoriasis Plaque Study Comparing Clobetasol Propionate Plus Calcipotriol Ointment With Clobetasol Propionate Ointment Alone, Calcipotriol Ointment Alone and a Vehicle Control for the Treatment of Psoriasis Vulgaris [NCT01043224]	Phase 1	24 participants (Actual)	Interventional	2010-01-31	Completed
A Single-Center, Randomized, Blinded, Vehicle- Controlled Exploratory Study to Assess the Activity of CRx-197 in Subjects With Plaque Psoriasis [NCT00796211]	Phase 2	20 participants (Anticipated)	Interventional	2008-11-30	Completed
A Phase Ib, Multi-Center, Randomized, Vehicle- and Comparator-Controlled Trial, Double-Blind for the Investigational Medicinal Products, Observer-Blind for the Comparators to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque [NCT04221906]	Phase 1	15 participants (Actual)	Interventional	2020-01-06	Completed
A Phase III, Multicentre, Randomized, Observer Blind, Parallel Group, Three Arms, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Topically Applied Calcipotriol/AKVANO 50 μg/g Cutaneous Solution Against Calcipotriol Ointment 50 Micrograms [NCT05174598]	Phase 3	278 participants (Actual)	Interventional	2018-10-03	Completed
Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial [NCT04071106]	Phase 2/Phase 3	50 participants (Anticipated)	Interventional	2019-09-01	Not yet recruiting
Combination Calcipotriene 0.005% Foam and Fluorouracil 5% Cream for the Treatment of Actinic Keratoses on the Scalp [NCT03996252]	Early Phase 1	15 participants (Actual)	Interventional	2019-07-01	Terminated(stopped due to The study team was not able to start the study and they never completed the IRB submission, so the study was terminated.)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd) to [NCT03731091]	Phase 3	494 participants (Actual)	Interventional	2018-10-31	Completed
LEO 19123 Cream in the Treatment of Psoriasis Vulgaris [NCT00764751]	Phase 2	51 participants (Actual)	Interventional	2008-09-30	Completed
A Double-Blind, Vehicle-Controlled, Rising Dose, Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis [NCT00820950]	Phase 2	29 participants (Actual)	Interventional	2007-05-31	Completed
A Randomized, Single-Blind, Active Control, 18-Week Study to Evaluate the Safety and Efficacy of A New Twice-Daily, Topically Applied LCD Solution vs. Calcipotriol Cream for the Treatment of Adult Subjects With Moderate Plaque Psoriasis [NCT00705900]		60 participants (Anticipated)	Interventional	2007-01-31	Completed
Comparative Effectiveness Trial of Topical Calcipotriene, Clobetasol, and Tacrolimus in the Treatment of Pediatric Plaque Morphea [NCT02680717]	Phase 1	0 participants (Actual)	Interventional	2016-03-31	Withdrawn(stopped due to Unable to obtain IRB approval at all sites)
Development of Vitamin D as a Therapy for Breast Cancer - Phase 2 [NCT00656019]	Phase 2	63 participants (Actual)	Interventional	2008-04-30	Completed
Xamiol® Gel in BODY Psoriasis : lonG-term Management of Psoriasis vUlgARis With Xamiol® Gel in Daily Clinical Practice of Russian Dermatologists. A Long-term Observational, Prospective Study [NCT02636101]		603 participants (Actual)	Observational	2016-01-31	Completed
[NCT02733874]	Phase 4	240 participants (Actual)	Interventional	2015-04-30	Completed
Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study [NCT02644954]	Phase 3	40 participants (Anticipated)	Interventional	2016-01-31	Not yet recruiting
Calcipotriol in the Prevention of Polymorphic Light Eruption [NCT00871052]		13 participants (Actual)	Interventional	2009-03-31	Completed
LEO19123 Cream in the Treatment of Hand Eczema [NCT00404196]	Phase 2	75 participants (Anticipated)	Interventional	2006-10-31	Completed
One-year Prospective, Observational Study of the Journey of Patients With Plaque Psoriasis Prescribed Calcipotriol/Betamethasone Aerosol Foam or Other Topical Therapy [NCT02935582]		1,214 participants (Actual)	Observational	2017-01-31	Completed
Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle, and the Gel Vehicle Alone in Scalp Psoriasis [NCT00216827]	Phase 3	1,485 participants	Interventional	2004-11-30	Completed
Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris [NCT02004574]	Phase 4	201 participants (Actual)	Interventional	2013-10-31	Completed
Efficacy and Safety of LEO 90105 Ointment (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris [NCT01422434]	Phase 3	676 participants (Actual)	Interventional	2011-07-31	Completed
The Role of Calcipotriol in Treatment of Pre-cancerous Skin Lesions [NCT02019355]	Early Phase 1	132 participants (Actual)	Interventional	2013-10-31	Completed
A 28-day, Double-blind, Randomized, Reference-controlled Psoriasis Plaque Test to Evaluate the Efficacy and Safety of Two Different BAY1003803 Formulation Types in 2 Concentrations Each in Treatment of Symptomatic Volunteers With Plaque-type Psoriasis [NCT02940002]	Phase 1	23 participants (Actual)	Interventional	2016-10-12	Completed
A Phase I, Single-Center, Randomized, Vehicle-Controlled Study, Double-Blind for the Study Preparations and Observer-Blind for the Comparators to Determine the Antipsoriatic Efficacy and Tolerability of Topical Formulations With Ciclosporin in a Psoriasis [NCT00578370]	Phase 1/Phase 2	25 participants (Anticipated)	Interventional	2007-11-30	Completed
Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis After Combination Treatment of Lexette and Sorilux for 2 Weeks [NCT04571151]	Phase 4	30 participants (Anticipated)	Interventional	2021-01-31	Not yet recruiting
The Maintenance Effect of Enstilar Foam in Combination With Otezla [NCT04555707]	Phase 4	30 participants (Anticipated)	Interventional	2020-06-24	Recruiting
Multicentre, Randomized, Investigator-Blinded, Parallel-group Study to Assess the Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis. [NCT01195831]	Phase 3	244 participants (Actual)	Interventional	2010-09-30	Completed
A Randomized, Multicenter STudy to Evaluate the Effect of Secukinumab 300 mg s.c. Administered During 52 Weeks to Patients Suffering From New-onset Moderate to Severe Plaque Psoriasis as Early Intervention Compared to Standard Treatment With Narrow-band U [NCT03020199]	Phase 4	196 participants (Actual)	Interventional	2017-03-27	Completed
A Double-Blind, Within-Subject Randomised, Placebo-Controlled, Proof of Concept, Comparison Study of SHP-141C Topical Cream in Psoriasis, Using the Microplaque Assay. [NCT01646567]	Phase 1	14 participants (Actual)	Interventional	2012-09-30	Completed
A Multicenter, Randomized, Double-Blind Study of the Safety and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam In The Treatment Of Moderate Plaque-Type Scalp And Body Psoriasis [NCT01139580]	Phase 3	363 participants (Actual)	Interventional	2010-05-31	Completed
Prospective, Observational, Non-interventional, Multicenter Study on the Efficacy and Tolerability of Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients With Plaque Psoriasis Under Daily Practice Conditions [NCT02881346]		410 participants (Actual)	Observational	2016-09-30	Completed
Nickel Desensitization Using Topical Therapy [NCT01413477]		24 participants (Anticipated)	Interventional	2011-08-31	Not yet recruiting
Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle and Calcipotriol in the Gel Vehicle in Scalp Psoriasis [NCT00216840]	Phase 3	1,350 participants	Interventional	2004-12-31	Completed
Long-term Treatment of Scalp Psoriasis With Calcipotriol Plus Betamethasone Dipropionate Gel [NCT00216879]	Phase 3	800 participants	Interventional	2005-02-28	Completed
An Open-Label, Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Biologic Agents [NCT03080545]	Phase 4	25 participants (Actual)	Interventional	2017-05-01	Completed
Efficacy and Safety of HAT1, a Novel Topical Therapeutic: An Open Label Pilot Study of HAT1 Compared to Calcipotriol in Patients With Chronic Plaque Psoriasis [NCT03069144]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2012-01-06	Completed
Phase 2 Study of the Role of Calcipotriol as Radioprotector of Skin in Women Receiving Radiotherapy Treatment to the Breast. [NCT00445250]	Phase 2	50 participants	Interventional		Not yet recruiting
A Psoriasis Plaque Test Comparing LEO 29102 Cream and Its Different Combinations to Daivobet® Ointment and a Vehicle Control for the Treatment of Psoriasis Vulgaris [NCT00875277]	Phase 2	24 participants (Actual)	Interventional	2009-04-30	Completed
Observational and Prospective Study in Patients With Nail Psoriasis Treated With Calcipotriene and Betamethasone Dipropionate Aerosol Foam to Evaluate the Change in the Severity of Psoriasis and in the Quality of Life [NCT04380597]		10 participants (Actual)	Observational	2019-03-26	Completed
Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas [NCT00691002]	Phase 3	1,245 participants (Actual)	Interventional	2008-05-31	Completed
Effect of Calcipotriol Plus Hydrocortisone Ointment on the Hypothalamic-pituitary-adrenal (HPA) Axis and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and on the Intertriginous Areas [NCT00704262]	Phase 2	33 participants (Actual)	Interventional	2008-05-31	Completed
An Open Label Study to Evaluate the Clinical Response to Sequential Treatment With Daivobet and Daivonex in Patients With Mild to Moderate Psoriasis [NCT00437619]	Phase 4	200 participants (Actual)	Interventional	2007-02-28	Completed
LEO19123 Cream in the Treatment of Atopic Dermatitis [NCT00392067]	Phase 2	75 participants (Anticipated)	Interventional	2006-10-31	Completed
A Phase I Exploratory Study Evaluating 3 Formulations of LEO 29102 Plus Calcipotriol, Ointment, LEO 29102 Ointment, Calcipotriol Ointment, Daivonex® Ointment and Diprosone® Ointment in the Treatment of Psoriasis [NCT01466478]	Phase 1	24 participants (Actual)	Interventional	2011-11-30	Completed
Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris [NCT00216892]	Phase 4	1,032 participants	Interventional	2005-04-30	Completed
A Phase 3 Study Comparing a Gel Containing Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) With Tacalcitol Ointment (4 mcg/g) and Gel Vehicle, Used Once Daily in the Treatment of Psoriasis Vulgaris [NCT00670241]	Phase 3	458 participants (Actual)	Interventional	2008-04-30	Completed
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris [NCT00817219]	Phase 2	33 participants (Actual)	Interventional	2009-07-31	Completed
A Pilot Study of Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia [NCT05416320]	Early Phase 1	0 participants (Actual)	Interventional	2023-08-31	Withdrawn(stopped due to The IRB was closed without enrolling any participants)
Calcipotriol Plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle and the Gel Vehicle Alone in Psoriasis Vulgaris [NCT00263718]	Phase 2	360 participants	Interventional	2005-12-31	Completed
Calcipotriol Plus Betamethasone Dipropionate Gel Compared to DAIVONEX/DOVONEX Scalp Solution in Patients With Scalp Psoriasis [NCT00243464]	Phase 3	300 participants	Interventional	2005-09-30	Completed
A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris [NCT00248456]	Phase 4	320 participants	Interventional	2005-10-31	Completed
Calcipotriene Plus Betamethasone Dipropionate Gel Compared to the Gel Vehicle in Scalp Psoriasis, in Patients Receiving Calcipotriene Plus Betamethasone Dipropionate Ointment for Psoriasis Vulgaris of Trunk/Limbs [NCT00279162]	Phase 3	160 participants (Anticipated)	Interventional	2005-12-31	Completed
An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab [NCT03827876]	Phase 4	30 participants (Anticipated)	Interventional	2019-01-16	Recruiting
Phase Ib, Two-centre, Randomised, Observer-blind, Placebo- and Comparator Controlled Trial to Evaluate the Safety, Tolerability and Antipsoriatic Efficacy of Three Strengths of a Topical SPS4251 Formulation in a Psoriasis Plaque Test [NCT01743118]	Phase 1	24 participants (Actual)	Interventional	2013-03-31	Completed
Evaluation of Topical Nicotinamide in Combination With Calcipotriol Compared With Calcipotriol Alone for the Treatment of Mild to Moderate Psoriasis. [NCT01763424]	Phase 2/Phase 3	66 participants (Actual)	Interventional	2011-07-31	Completed
A Phase 2 Study Comparing Treatment With LEO 90100 With Calcipotriol Plus Betamethasone Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris. [NCT01536886]	Phase 2	376 participants (Actual)	Interventional	2012-05-31	Completed
[NCT01536938]	Phase 2	303 participants (Actual)	Interventional	2012-05-31	Completed
The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients [NCT03848871]	Phase 4	20 participants (Actual)	Interventional	2017-12-12	Completed
Molecular Effects of Topical Calcipotriene on Morphea [NCT02411643]	Early Phase 1	2 participants (Actual)	Interventional	2015-03-31	Terminated(stopped due to Accrual incomplete/Investigator left institution)
Evaluation of the Efficacy and Safety of Indigo Naturalis Oil Extract and Calcipotriol Solution in Patients With Nail Psoriasis [NCT01445886]	Phase 2/Phase 3	33 participants (Actual)	Interventional	2011-01-31	Completed
A Phase 1 Randomized, Placebo and Active Comparator-controlled Trial, Double-blind for the IPs, Observer-blind for the Active Comparator, to Assess the Potency of SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment in a Psoriasis Plaque Test [NCT03004339]	Phase 1	13 participants (Actual)	Interventional	2016-08-31	Completed
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris [NCT01707043]	Phase 4	20 participants (Actual)	Interventional	2012-10-31	Completed
A Randomized Phase III, Three-parallel Arm, Assessor Blind, Multi-centre Study to Evaluate the Efficacy, Safety and Tolerability of AKP02 Cutaneous Spray Versus Enstilar Cutaneous Foam in Subjects With Mild to Moderate Psoriasis. [NCT05249972]	Phase 3	294 participants (Anticipated)	Interventional	2022-01-24	Recruiting
A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris [NCT01268527]	Phase 2	30 participants (Actual)	Interventional	2010-03-15	Completed
Phase IIA, Single-Arm, Open- Label, Clinical Trial of Calcipotriene Plus 5-Fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients [NCT05699603]	Phase 2	56 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
The Effect of Preceding Fractional Co2 Laser Either With Tacrolimus, Calcipotriol or With NB-UVB in the Treatment of Stable Generalized Vitiligo [NCT03234673]	Phase 1	30 participants (Anticipated)	Interventional	2017-08-31	Not yet recruiting
An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis [NCT00437255]	Phase 4	122 participants (Actual)	Interventional	2006-08-31	Completed
Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis [NCT01745133]	Phase 4	63 participants (Actual)	Interventional	2013-01-31	Completed
A Phase 1, Single- Center, Randomized, Double-blind, Vehicle And Active Comparator-controlled Trial To Evaluate The Antipsoriatic Activity And Safety Of A Topically Applied Pf-06263276 Formulation In A Psoriasis Plaque Test [NCT02193815]	Phase 1	15 participants (Actual)	Interventional	2014-09-30	Completed
A Phase 3 Study Comparing Once Daily Treatment With Calcipotriol 50 mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension With Betamethasone 0.5 mg/g (as Dipropionate) in the Topical Suspension Vehicle, Calcipotriol 50 mcg/g in the Topica [NCT01188928]	Phase 3	1,152 participants (Actual)	Interventional	2010-09-30	Completed
Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Mild Breakthrough in Moderate to Severe Plaque Psoriasis Patients Receiving Efalizumab ( Raptiva). [NCT00608777]	Phase 4	6 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to Withdrawal of marketing autorization of efalizumab by the EMEA.)
Efficacy of Topical Calcipotriol-assisted Ablative Fractional Laser Photodynamic Therapy for the Treatment of Actinic Keratosis: 12-month Follow-up Results of a Prospective, Randomised, Comparative Trial [NCT02976727]	Phase 1	48 participants (Actual)	Interventional	2014-05-31	Completed
Efficacy of Calcipotriol Assisted MAL-PDT Versus Conventional MAL-PDT for Actinic Keratosis: a Randomized and Controlled Study [NCT02878382]		20 participants (Actual)	Interventional	2016-10-31	Completed
Can an App Supporting Psoriasis Patients Improve Adherence to Topical Treatment? A Single-blind Randomized Controlled Trial [NCT02858713]	Phase 4	134 participants (Actual)	Interventional	2017-01-09	Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Lt [NCT03331523]	Phase 3	643 participants (Actual)	Interventional	2017-10-20	Completed
A Single-Center, Randomized, Observer Blind, Vehicle- and Comparator-controlled Trial to Evaluate the Antipsoriatic Efficacy and Safety of Topical Formulations of C-82 in a Psoriasis Plaque Test [NCT02432027]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2015-06-30	Completed
A Randomized, Doubleblind, Vehicle-controlled, Parallel-group Trial to Assess the Efficacy, Safety and Tolerability of P-3073 for Topical Treatment of Nail Psoriasis [NCT03079973]	Phase 3	0 participants (Actual)	Interventional	2017-05-15	Withdrawn(stopped due to Project development priorities changed.)
Innate Immunity in Acne Vulgaris [NCT01694433]	Phase 2/Phase 3	66 participants (Actual)	Interventional	2013-02-28	Completed
A Phase 3 Study Comparing an Ointment Containing Calcipotriol 25 mcg/g Plus Hydrocortisone 10 mg g With Tacalcitol 4 mcg/g Ointment and the Ointment Vehicle Alone, All Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and on the Intert [NCT00640822]	Phase 3	782 participants (Actual)	Interventional	2008-02-29	Completed
[NCT01837576]	Phase 1	24 participants (Actual)	Interventional	2013-04-30	Completed
Comparison of the Efficacy of Tacrolimus 0.1% Ointment vs Calcipotriol/Betamethasone in Combination With NBUVB in Treatment of Vitiligo [NCT04440371]		40 participants (Anticipated)	Interventional	2020-06-21	Active, not recruiting
Clinical Effectiveness of Calcipotriene in Acute Graft Versus Host Disease of the Skin: A Pilot Study [NCT03093805]		10 participants (Actual)	Interventional	2017-03-15	Completed
LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris [NCT02132936]	Phase 3	504 participants (Actual)	Interventional	2014-06-30	Completed
Combination Topical 5-fluorouracil 5% / Calcipotriene 0.005% Cream for Treatment of in Situ and Superficially Invasive Squamous Cell Carcinoma of the Skin [NCT04839731]	Early Phase 1	30 participants (Anticipated)	Interventional	2021-04-14	Recruiting
A Pilot Trial of Topical Calcipotriene Treatment for Breast Cancer Immunoprevention [NCT03596073]	Phase 1	120 participants (Anticipated)	Interventional	2018-11-07	Recruiting
A Randomized, Double-Blind Study Comparing TOLMAR Calcipotriene and Betamethasone Suspension to Reference Listed Drug in the Treatment of Scalp Psoriasis [NCT03122353]	Phase 1	699 participants (Actual)	Interventional	2017-04-11	Completed
Calcipotriol /Betamethasone Ointment Versus Fractional CO2 Laser Plus Calcipotriol /Betamethasone Ointment in the Treatment of Plaque Psoriasis: Randomized Comparative Study [NCT06011083]		40 participants (Actual)	Interventional	2022-08-01	Completed
Open Clinical Study, Comparing Non-inferiority for Efficacy of the Drug Tazarotene 0.1% Versus the Comparator Drug Calcipotriol 0.005% in the Treatment of Chronic Plaque Psoriasis [NCT01279629]		50 participants (Anticipated)	Observational	2011-02-28	Suspended
A Study to Investigate the Irritation Potential on Healthy Intact Skin and Effect on Psoriatic Skin of Topical Applications of GW786034 [NCT00358384]	Phase 1	10 participants (Actual)	Interventional	2005-09-26	Completed
A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris [NCT01580488]	Phase 1	24 participants (Actual)	Interventional	2012-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00574249 (18) [back to overview]	Percent Change in Psoriasis Scalp Severity Index (PSSI) From Baseline to Week 16.
NCT00574249 (18) [back to overview]	Percent Change in Nail Psoriasis Severity Index (NAPSI) at Week 16.
NCT00574249 (18) [back to overview]	Percentage of Participants With a PASI90 Response at Week 16 Compared With Baseline (Week 0)
NCT00574249 (18) [back to overview]	Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 16 Compared With Baseline (Week 0)
NCT00574249 (18) [back to overview]	Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 8 Compared With Baseline (Week 0)
NCT00574249 (18) [back to overview]	Percent Change in the Dermatology Life Quality Index (DLQI) Total Score at Week 2 Compared With Baseline (Week 0)
NCT00574249 (18) [back to overview]	Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 12
NCT00574249 (18) [back to overview]	Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 12 Compared With Baseline (Week 0)
NCT00574249 (18) [back to overview]	Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 2
NCT00574249 (18) [back to overview]	Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 4
NCT00574249 (18) [back to overview]	Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 8
NCT00574249 (18) [back to overview]	Percentage of Participants Achieving a Physicians Global Assessment (PGA) Response of Clear or Minimal at Week 16
NCT00574249 (18) [back to overview]	Percentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0)
NCT00574249 (18) [back to overview]	Percentage of Participants With a PASI100 Response at Week 16 Compared With Baseline (Week 0)
NCT00574249 (18) [back to overview]	Percentage of Participants With a PASI50 Response at Week 16 Compared With Baseline (Week 0)
NCT00574249 (18) [back to overview]	Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16 Compared With Baseline (Week 0)
NCT00574249 (18) [back to overview]	Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 4 Compared With Baseline (Week 0)
NCT00574249 (18) [back to overview]	Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 8 Compared With Baseline (Week 0)
NCT00640822 (1) [back to overview]	Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8
NCT00656019 (1) [back to overview]	Correlation of Vitamin D Levels, Prognostic Factors, and Gene Expression Profile in Patients With Breast Cancer
NCT00670241 (5) [back to overview]	Subjects With Relapse During the Study
NCT00670241 (5) [back to overview]	Subjects With Rebound During the Study
NCT00670241 (5) [back to overview]	"Subjects With Controlled Disease According to the Investigator's Global Assessment of Disease Severity at Week 4"
NCT00670241 (5) [back to overview]	The Percentage Change in PASI From Baseline to Week 8
NCT00670241 (5) [back to overview]	"Subjects With Controlled Disease (Clear or Almost Clear Disease) According to Investigator's Global Assessment of Disease Severity at Week 8"
NCT00691002 (5) [back to overview]	"Participants With Success According to Total Sign Score (TSS) of the Face at Week 8 (Visit 6) in the Double-blind Phase"
NCT00691002 (5) [back to overview]	"Participants With Success According to Total Sign Score of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase"
NCT00691002 (5) [back to overview]	"Participants With Controlled Disease According to the IGA of Disease Severity of the Face at Week 4 (Visit 4) in the Double-blind Phase"
NCT00691002 (5) [back to overview]	"Participants With Controlled Disease According to the IGA of Disease Severity of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase"
NCT00691002 (5) [back to overview]	"Participants With Controlled Disease According to the Investigator's Global Assessment(IGA) of Disease Severity of the Face at Week 8 (Visit 6) in the Double-blind Phase"
NCT00704262 (13) [back to overview]	Serum Cortisol Concentration After 30 Minutes
NCT00704262 (13) [back to overview]	Overall Disease Severity of the Face According to the IGA
NCT00704262 (13) [back to overview]	Albumin Corrected Serum Calcium Values Above the Upper Limit of the Reference Range
NCT00704262 (13) [back to overview]	"Participants With Controlled Disease (Clear or Almost Clear) According to the Investigator's Global Assessment of Disease Severity (IGA) of the Face"
NCT00704262 (13) [back to overview]	"Participants With Controlled Disease (Clear or Almost Clear) According to the IGA of the Intertriginous Areas"
NCT00704262 (13) [back to overview]	The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 60 Minutes
NCT00704262 (13) [back to overview]	The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 Minutes
NCT00704262 (13) [back to overview]	The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 and 60 Minutes
NCT00704262 (13) [back to overview]	Overall Disease Severity of Intertriginous Areas According to the IGA
NCT00704262 (13) [back to overview]	Serum Cortisol Concentration After 60 Minutes
NCT00704262 (13) [back to overview]	Albumin Corrected Serum Calcium
NCT00704262 (13) [back to overview]	Change in Albumin Corrected Serum Calcium
NCT00704262 (13) [back to overview]	Change in Albumin Corrected Serum Calcium
NCT00764751 (4) [back to overview]	The Absolute Change in PASI (Psoriasis Area Severity Index)
NCT00764751 (4) [back to overview]	The Percentage Change in PASI (Psoriasis Area Severity Index)
NCT00764751 (4) [back to overview]	Participant's Overall Assessment of Treatment Response
NCT00764751 (4) [back to overview]	Participant's Assessment of Treatment Preference
NCT00817219 (10) [back to overview]	Change in Urinary Calcium:Creatinine Ratio From Baseline to End of Treatment.
NCT00817219 (10) [back to overview]	Serum Cortisol Concentration of ≤18 mcg/dL at 30 Minutes After ACTH-challenge at End of Treatment
NCT00817219 (10) [back to overview]	Serum Cortisol Concentration of ≤18 mcg/dL at 30 and 60 Minutes After ACTH-challenge at End of Treatment
NCT00817219 (10) [back to overview]	PASI 75 at Week 4.
NCT00817219 (10) [back to overview]	PASI 50 at Week 4.
NCT00817219 (10) [back to overview]	Change in Albumin Corrected Serum Calcium From Baseline to End of Treatment
NCT00817219 (10) [back to overview]	Adverse Drug Reactions
NCT00817219 (10) [back to overview]	"Controlled Disease(i.e., Clear or Very Mild) According to the Patient's Global Assessment of Disease Severity at Week 4."
NCT00817219 (10) [back to overview]	"Controlled Disease(i.e., Clear or Almost Clear) According to the Investigator's Global Assessment of Disease Severity at Week 4."
NCT00817219 (10) [back to overview]	Percentage Change in PASI From Baseline to Week 4.
NCT00820950 (6) [back to overview]	Change in Target Lesion TOTAL Score (Sum of Erythema + Scaling + Thickness) Compared to Baseline
NCT00820950 (6) [back to overview]	Change in Target Lesion Area Compared to Baseline
NCT00820950 (6) [back to overview]	Number of Participants With Treatment Emergent Adverse Events
NCT00820950 (6) [back to overview]	Pharmacokinetics Parameter : Bioavailability of INCB018424
NCT00820950 (6) [back to overview]	Pharmacokinetics Parameter : Skin Flux of INCB018424
NCT00820950 (6) [back to overview]	Change in Target Lesion Individual Component Scores for Erythema, Scaling and Thickness Compared to Baseline
NCT00875277 (13) [back to overview]	Change in Infiltration Compared to Baseline
NCT00875277 (13) [back to overview]	Biomarkers by Immunochemistry
NCT00875277 (13) [back to overview]	Pathology and Histology by Treatment: Epidermal Thickness
NCT00875277 (13) [back to overview]	Pathology and Histology by Treatment: Frequency of Neutrophil Abscesses
NCT00875277 (13) [back to overview]	Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1)
NCT00875277 (13) [back to overview]	Biomarkers by Immunochemistry: Epidermal Proliferation
NCT00875277 (13) [back to overview]	Ultrasonography: Change in Lesions Thickness From Baseline Measured by Ultrasound
NCT00875277 (13) [back to overview]	Pathology and Histology by Treatment
NCT00875277 (13) [back to overview]	Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline
NCT00875277 (13) [back to overview]	Change in Single Clinical Symptom Score: Erythema, Scaling, Infiltration Compared to Baseline
NCT00875277 (13) [back to overview]	Change in Scaling Compared to Baseline
NCT00875277 (13) [back to overview]	Change in Erythema Compared to Baseline
NCT00875277 (13) [back to overview]	Biomarkers by Immunochemistry: Epidermal Differentiation
NCT01139580 (6) [back to overview]	Number of Participants With a Target Lesion Score of 0 or 1 for Erythema and at Least a 2 Grade Improvement From Baseline at Week 8
NCT01139580 (6) [back to overview]	Number of Participants With an ISGA Score of Clear (0) or Almost Clear (1) for Body Involvement at Week 8
NCT01139580 (6) [back to overview]	Number of Participants With an ISGA Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8 Using Last Observation Carried Forward (LOCF)
NCT01139580 (6) [back to overview]	Number of Participants With an Investigator's Static Global Assessment (ISGA) Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8 Using the Failure Method
NCT01139580 (6) [back to overview]	Number of Participants With a Target Lesion Score of 0 or 1 for Scaling and at Least a 2 Grade Improvement From Baseline at Week 8
NCT01139580 (6) [back to overview]	Number of Participants With a Target Lesion Score of 0 or 1 for Plaque Thickness at Week 8
NCT01188928 (4) [back to overview]	Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4
NCT01188928 (4) [back to overview]	Mean Percentage Change in PASI From Baseline to Week 8
NCT01188928 (4) [back to overview]	Mean Percentage Change in PASI From Baseline to Week 4
NCT01188928 (4) [back to overview]	Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 8
NCT01195831 (5) [back to overview]	Patients With Success (Total Sign Score ≤1) at Week 4
NCT01195831 (5) [back to overview]	"Patients With Controlled Disease in Terms of Clear or Very Mild According to Patient's Global Assessment of Disease Severity at Week 2."
NCT01195831 (5) [back to overview]	"Patients With Controlled Disease in Terms of Clear or Minimal According to Investigator's Global Assessment of Disease Severity at Week 4."
NCT01195831 (5) [back to overview]	"Patients With Controlled Disease in Terms of Clear or Minimal According to Investigator's Global Assessment of Disease Severity at Week 2"
NCT01195831 (5) [back to overview]	"Patients With Controlled Disease in Term of Clear or Very Mild According to Patient's Global Assessment of Disease Severity at Week 4."
NCT01268527 (6) [back to overview]	Overview of Treatment-Emergent Adverse Events (TEAEs)
NCT01268527 (6) [back to overview]	Clinical (Global) Assessment of Efficacy at Day 12/Discontinuation
NCT01268527 (6) [back to overview]	Clinical (Global) Assessment of Efficacy on Day 8
NCT01268527 (6) [back to overview]	Summary Statistics and Primary Pairwise Comparison (Vehicle-E6201) of Area Under the Curve (AUC) for the Baseline-Corrected Thickness of the Psoriatic Infiltrate
NCT01268527 (6) [back to overview]	Change in Thickness of the Psoriatic Infiltrate From Baseline to End of Treatment (Day 12/Discontinuation)
NCT01268527 (6) [back to overview]	Change in Thickness of the Psoriatic Infiltrate From Baseline to Day 8
NCT01422434 (4) [back to overview]	Change in mPASI From Baseline to Week 1
NCT01422434 (4) [back to overview]	Physician's Global Assessment of Psoriasis
NCT01422434 (4) [back to overview]	Change From Baseline in Modified Psoriasis Area and Severity Index (mPASI)
NCT01422434 (4) [back to overview]	Change From Baseline in Target Lesion Assessment
NCT01445886 (3) [back to overview]	Change From Baseline in Modified Target NAPSI for the Single Most Severely Affected Nail
NCT01445886 (3) [back to overview]	Change From Baseline in Single-handed Nail Psoriasis Severity Index (shNAPSI) at 24 Weeks
NCT01445886 (3) [back to overview]	Physician's and Subject's Global Assessment
NCT01536886 (1) [back to overview]	Subjects With 'Controlled Disease' ('Clear'/'Almost Clear' for Subjects w. at Least Moderate Disease at Baseline, 'Clear' for Subjects With Mild Disease at Baseline) According to the Investigator's Global Assessment (IGA) on the Trunk and Limbs at Week 4.
NCT01536938 (1) [back to overview]	Subjects With 'Controlled Disease' ('Clear'/'Almost Clear' for Subjects w. at Least Moderate Disease at Baseline, 'Clear' for Subjects With Mild Disease at Baseline) According to the Investigator's Global Assessment (IGA) on the Trunk and Limbs at Week 4.
NCT01580488 (6) [back to overview]	Change in Lesion Thickness From Baseline to Day 22
NCT01580488 (6) [back to overview]	Change in Infiltration From Baseline to Day 22
NCT01580488 (6) [back to overview]	Change in Erythema From Baseline to Day 22
NCT01580488 (6) [back to overview]	Change in the Total Clinical Score From Baseline to Day 22
NCT01580488 (6) [back to overview]	Change in Scaling From Baseline to Day 22
NCT01580488 (6) [back to overview]	Change in Skin Thickness From Baseline to Day 22
NCT01694433 (2) [back to overview]	Lesion Counts (Total, Inflammatory and Non-inflammatory)
NCT01694433 (2) [back to overview]	Acne Severity as Assessed With the Investigator's Global Assessment (IGA)
NCT01707043 (2) [back to overview]	Subjective Subject Preference Survey for the First Treatment Session
NCT01707043 (2) [back to overview]	Subjective Subject Preference Survey for the Second Treatment Session
NCT01745133 (1) [back to overview]	Physician Global Assessement
NCT02132936 (5) [back to overview]	Treatment Success According to the PGA
NCT02132936 (5) [back to overview]	Subjects With PASI 75 at Week 4 for LEO 90100 and at Week 8 for Calcipotriol BDP Gel.
NCT02132936 (5) [back to overview]	Change in Itch as Assessed on a VAS Scale From Baseline to Week 4 (LEO 90100) vs. Week 8 (Calcipotriol BDP Gel).
NCT02132936 (5) [back to overview]	Change in Itch as Assessed on a VAS Scale (LEO 90100 vs. the Foam Vehicle Group).
NCT02132936 (5) [back to overview]	Time to 'Treatment Success' According to PGA.
NCT02193815 (9) [back to overview]	Change From Baseline in Psoriatic Skin Thickness/EPB for Tofacitinib 2% Ointment in Comparison to Corresponding Vehicle at Day 12
NCT02193815 (9) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs): Specified Skin AEs
NCT02193815 (9) [back to overview]	Number of Participants With Potentially Clinically Significant Vital Signs Findings
NCT02193815 (9) [back to overview]	Global Clinical Assessment at Day 1, 8 and 12
NCT02193815 (9) [back to overview]	Area Under the Curve (AUC) of Psoriatic Skin Thickness/EPB
NCT02193815 (9) [back to overview]	Change From Baseline in Psoriatic Skin Thickness/EPB for PF-06263276 4% Solution in Comparison to Daivonex Solution at Day 12
NCT02193815 (9) [back to overview]	Number of Participants With Laboratory Abnormalities Meeting the Criteria for Potential Clinical Concern
NCT02193815 (9) [back to overview]	Change From Baseline in Psoriatic Skin Thickness/Echo-Poor Band (EPB) for PF-06263276 4% Solution in Comparison to Corresponding Vehicle at Day 12
NCT02193815 (9) [back to overview]	Change From Baseline in Psoriatic Skin Thickness/EPB at Day 8
NCT02858713 (3) [back to overview]	Dermatology Life Quality Index (DLQI)
NCT02858713 (3) [back to overview]	Lattice-System Physician's Global Assessment (LS-PGA)
NCT02858713 (3) [back to overview]	Percentage of Adherent Participants
NCT02878382 (4) [back to overview]	Change From Baseline in Fluorescence Intensity of PPIX
NCT02878382 (4) [back to overview]	Changes From Baseline in Actinic Keratosis - Lesion Base Count.
NCT02878382 (4) [back to overview]	Percentage of Actinic Keratosis (AK) Lesions Cleared
NCT02878382 (4) [back to overview]	Pain Scores Immediately Post Illumination
NCT03441789 (6) [back to overview]	Per Cent of Patients With at Least 1-grade Improvement in Physicians Global Assessment (PGA) at Week 4 and Week 12 and Week 16
NCT03441789 (6) [back to overview]	Percent of Subjects With PASI 75 at Week 4 and Week 12
NCT03441789 (6) [back to overview]	Percent of Subjects With PASI 90 and 100 at Week 16
NCT03441789 (6) [back to overview]	Global Percent Improvement in Dermatologic Quality of Life Index (DLQI) at Week 4, 12, and 16
NCT03441789 (6) [back to overview]	Percent of Subjects With a Psoriasis Assessment and Severity Index (PASI) 75 at Week 16
NCT03441789 (6) [back to overview]	Global Improvement in Itch Visual Analogue Scale (VAS) at Week 4,12 and 16
NCT03469336 (8) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (AEs)
NCT03469336 (8) [back to overview]	Area Under the Curve of the Psoriatic Skin Infiltrate Thickness
NCT03469336 (8) [back to overview]	Change From Baseline in Psoriatic Skin Infiltrate Thickness
NCT03469336 (8) [back to overview]	Number of Participants With Post-Baseline Vital Signs Data Meeting Categorical Summarization Criteria
NCT03469336 (8) [back to overview]	Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
NCT03469336 (8) [back to overview]	Number of Participants With Electrocardiogram (ECG) Data Meeting Pre-specified Criteria
NCT03469336 (8) [back to overview]	Change From Baseline in Skin Infiltrate Thickness in Response to PF-06763809 Compared to Calcipotriene/Calcipotriol Solution.
NCT03469336 (8) [back to overview]	Change From Baseline in Skin Infiltrate Thickness in Response to PF-06763809 Compared to Betamethasone Solution.
NCT03848871 (6) [back to overview]	Change in TLSS (Total Lesion Severity Score) From Baseline to Week 2 and Week 4 - Assessment of Erythema
NCT03848871 (6) [back to overview]	Change in TLSS (Total Lesion Severity Score) From Baseline to Week 2 and Week 4 - Assessment of Induration
NCT03848871 (6) [back to overview]	Change in Body Surface Area (BSA) From Baseline to Week 2 and Week 4
NCT03848871 (6) [back to overview]	Change in TLSS (Total Lesion Severity Score) From Baseline to Week 2 and Week 4 - Assessment of Scaling
NCT03848871 (6) [back to overview]	Change in Lesion Size From Baseline to Week 2 and Week 4
NCT03848871 (6) [back to overview]	Change in Physicians Global Assessment (PGA) From Baseline to Week 2 and Week 4

Percent Change in Psoriasis Scalp Severity Index (PSSI) From Baseline to Week 16.

PSSI is a physician assessment of clinical symptoms of scalp psoriasis. Computed as the sum of scores for erythema, induration, and desquamation (1 = absent; 4 = severest possible) multiplied by involved area (0 = 0%; 6 = 90-100%). Total score range: 0 (best) to 72 (worst). Negative change and percent change from Baseline indicate improvement. (NCT00574249)
Timeframe: Week 0 and Week 16

Intervention	percent change in score (Median)
Adalimumab + Placebo	-100.00
Adalimumab + Calcipotriol/Betamethasone	-100.00

Intervention	percent change in score (Median)
Adalimumab + Placebo	-40.00
Adalimumab + Calcipotriol/Betamethasone	-37.50

Intervention	percentage of participants (Number)
Adalimumab + Placebo	50.3
Adalimumab + Calcipotriol/Betamethasone	38.8

Intervention	percent change in score (Mean)
Adalimumab + Placebo	20.53
Adalimumab + Calcipotriol/Betamethasone	19.71

Intervention	percent change in score (Mean)
Adalimumab + Placebo	19.35
Adalimumab + Calcipotriol/Betamethasone	18.22

Intervention	percent change in score (Mean)
Adalimumab + Placebo	-32.14
Adalimumab + Calcipotriol/Betamethasone	-47.49

Intervention	percentage of participants (Number)
Adalimumab + Placebo	64.8
Adalimumab + Calcipotriol/Betamethasone	50.0

Intervention	percent change in score (Mean)
Adalimumab + Placebo	-69.49
Adalimumab + Calcipotriol/Betamethasone	-66.75

Intervention	percentage of participants (Number)
Adalimumab + Placebo	7.1
Adalimumab + Calcipotriol/Betamethasone	13.9

Intervention	percentage of participants (Number)
Adalimumab + Placebo	24.5
Adalimumab + Calcipotriol/Betamethasone	33.1

Intervention	percentage of participants (Number)
Adalimumab + Placebo	46.2
Adalimumab + Calcipotriol/Betamethasone	42.9

Intervention	percentage of participants (Number)
Normal Vitamin D Levels	0
Low-normal Vitamin D Levels	0
Low Vitamin D Levels	0
Very-low Vitamin D Levels	0

Intervention	percentage of participants (Number)
Adalimumab + Placebo	64.6
Adalimumab + Calcipotriol/Betamethasone	56.6

Intervention	percentage of participants (Number)
Adalimumab + Placebo	70.9
Adalimumab + Calcipotriol/Betamethasone	64.8

Intervention	percentage of participants (Number)
Adalimumab + Placebo	24.2
Adalimumab + Calcipotriol/Betamethasone	15.3

Intervention	percentage of participants (Number)
Adalimumab + Placebo	82.7
Adalimumab + Calcipotriol/Betamethasone	80.9

Intervention	percent change in score (Mean)
Adalimumab + Placebo	-71.46
Adalimumab + Calcipotriol/Betamethasone	-67.20

Intervention	percent change in score (Mean)
Adalimumab + Placebo	-46.64
Adalimumab + Calcipotriol/Betamethasone	-60.93

Intervention	percent change in score (Mean)
Adalimumab + Placebo	-63.30
Adalimumab + Calcipotriol/Betamethasone	-62.30

Intervention	Participants (Number)
Calcipotriol Plus Hydrocortisone Ointment	183
Tacalcitol Ointment	147
Calcipotriol Plus Hydrocortisone Ointment Vehicle	37

Intervention	participants (Number)
Calcipotriol Plus Betamethasone Dipropionate Gel	28
Tacalcitol Ointment	7
Gel Vehicle	3

Intervention	Percent change in PASI score (Number)
Calcipotriol Plus Betamethasone Dipropionate Gel	-57.0
Tacalcitol Ointment	-41.9
Gel Vehicle	-17.9

calcipotriene

Description

Cross-References

Synonyms (129)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (6)

Protein Targets (4)

Potency Measurements

Activation Measurements

Biological Processes (28)

Molecular Functions (12)

Ceullar Components (6)

Bioassays (51)

Research

Studies (1,063)

Study Types

Clinical Trials (121)

Trial Overview

Trial Outcomes

Percent Change in Psoriasis Scalp Severity Index (PSSI) From Baseline to Week 16.

Percent Change in Nail Psoriasis Severity Index (NAPSI) at Week 16.

Percentage of Participants With a PASI90 Response at Week 16 Compared With Baseline (Week 0)

Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 16 Compared With Baseline (Week 0)

Percent Change in Short Form 36 Health Survey (SF-36) Physical Component Score (PCS) at Week 8 Compared With Baseline (Week 0)

Percent Change in the Dermatology Life Quality Index (DLQI) Total Score at Week 2 Compared With Baseline (Week 0)

Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 12

Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 12 Compared With Baseline (Week 0)

Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 2

Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 4

Percentage of Participants Achieving a Physician's Global Assessment (PGA) of Clear or Minimal at Week 8

Percentage of Participants Achieving a Physicians Global Assessment (PGA) Response of Clear or Minimal at Week 16

Percentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0)

Percentage of Participants With a PASI100 Response at Week 16 Compared With Baseline (Week 0)

Percentage of Participants With a PASI50 Response at Week 16 Compared With Baseline (Week 0)

Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16 Compared With Baseline (Week 0)

Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 4 Compared With Baseline (Week 0)

Percent Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 8 Compared With Baseline (Week 0)

Subjects With Controlled Disease According to the Investigator Assessment of the Face at Week 8

Correlation of Vitamin D Levels, Prognostic Factors, and Gene Expression Profile in Patients With Breast Cancer

Subjects With Relapse During the Study

Subjects With Rebound During the Study

"Subjects With Controlled Disease According to the Investigator's Global Assessment of Disease Severity at Week 4"

The Percentage Change in PASI From Baseline to Week 8

"Subjects With Controlled Disease (Clear or Almost Clear Disease) According to Investigator's Global Assessment of Disease Severity at Week 8"

"Participants With Success According to Total Sign Score (TSS) of the Face at Week 8 (Visit 6) in the Double-blind Phase"

"Participants With Success According to Total Sign Score of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase"

"Participants With Controlled Disease According to the IGA of Disease Severity of the Face at Week 4 (Visit 4) in the Double-blind Phase"

"Participants With Controlled Disease According to the IGA of Disease Severity of the Intertriginous Areas at Week 8 (Visit 6) in the Double-blind Phase"

"Participants With Controlled Disease According to the Investigator's Global Assessment(IGA) of Disease Severity of the Face at Week 8 (Visit 6) in the Double-blind Phase"

Serum Cortisol Concentration After 30 Minutes

Overall Disease Severity of the Face According to the IGA

Albumin Corrected Serum Calcium Values Above the Upper Limit of the Reference Range

"Participants With Controlled Disease (Clear or Almost Clear) According to the Investigator's Global Assessment of Disease Severity (IGA) of the Face"

"Participants With Controlled Disease (Clear or Almost Clear) According to the IGA of the Intertriginous Areas"

The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 60 Minutes

The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 Minutes

The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 and 60 Minutes

Overall Disease Severity of Intertriginous Areas According to the IGA

Serum Cortisol Concentration After 60 Minutes

Albumin Corrected Serum Calcium

Change in Albumin Corrected Serum Calcium

Change in Albumin Corrected Serum Calcium

The Absolute Change in PASI (Psoriasis Area Severity Index)

The Percentage Change in PASI (Psoriasis Area Severity Index)

Participant's Overall Assessment of Treatment Response

Participant's Assessment of Treatment Preference

Change in Urinary Calcium:Creatinine Ratio From Baseline to End of Treatment.

Serum Cortisol Concentration of ≤18 mcg/dL at 30 Minutes After ACTH-challenge at End of Treatment

Serum Cortisol Concentration of ≤18 mcg/dL at 30 and 60 Minutes After ACTH-challenge at End of Treatment

PASI 75 at Week 4.

PASI 50 at Week 4.

Change in Albumin Corrected Serum Calcium From Baseline to End of Treatment

Adverse Drug Reactions

"Controlled Disease(i.e., Clear or Very Mild) According to the Patient's Global Assessment of Disease Severity at Week 4."

Intervention	Participants (Count of Participants)
LEO 80190	171
Calcipotriol	136
Hydrocortisone	131
LEO 80190 Vehicle	42

Intervention	mcg/dL (Mean)
	Week 4 (Day 28)	Week 8 (Day 56)
Calcipotriol Plus Hydrocortisone (LEO 80190)	25.29	25.93

Intervention	Participants (Count of Participants)
	Baseline72237955						Week 2 (Day 14)72237955	Week 4 (Day 28)72237955	Week 6 (Day 42)72237955	Week 8 (Day 56)72237955	End of Treatment (last value recorded)72237955
	Mild	Moderate	Severe	Very severe	Clear	Almost clear
Calcipotriol Plus Hydrocortisone (LEO 80190)	27
Calcipotriol Plus Hydrocortisone (LEO 80190)	12
Calcipotriol Plus Hydrocortisone (LEO 80190)	16
Calcipotriol Plus Hydrocortisone (LEO 80190)	9
Calcipotriol Plus Hydrocortisone (LEO 80190)	2
Calcipotriol Plus Hydrocortisone (LEO 80190)	1
Calcipotriol Plus Hydrocortisone (LEO 80190)	0
Calcipotriol Plus Hydrocortisone (LEO 80190)	5
Calcipotriol Plus Hydrocortisone (LEO 80190)	15
Calcipotriol Plus Hydrocortisone (LEO 80190)	7
Calcipotriol Plus Hydrocortisone (LEO 80190)	14
Calcipotriol Plus Hydrocortisone (LEO 80190)	6
Calcipotriol Plus Hydrocortisone (LEO 80190)	3

Intervention	Participants (Count of Participants)
	>18 mcg/dL	≤18 mcg/dL
Calcipotriol Plus Hydrocortisone (LEO 80190)	30	0

Intervention	mmol/L (Mean)
	Week 2 (Day 14)	Week 4 (Day 28)	Week 6 (Day 42)	Week 8 (Day 56)	End of Treatment (last value recorded)
Calcipotriol Plus Hydrocortisone (LEO 80190)	2.233	2.217	2.208	2.179	2.182

Intervention	mmol/L (Mean)
	Baseline	Week 2 (Day 14)	Week 6 (Day 42)
Calcipotriol Plus Hydrocortisone (LEO 80190)	2.215	0.018	-0.013

Intervention	units on a scale (Mean)
Group A: LEO 19123	-2.6
Group A: Dovonex®	-3.8
Group B: LEO 19123	-4.2
Group B: LEO 19123 Vehicle	-2.5

Intervention	percentage change in PASI (Mean)
Group A: LEO 19123	-24.8
Group A: Dovonex®	-40.2
Group B: LEO 19123	-46.8
Group B: LEO 19123 Vehicle	-29.8

Intervention	Participants (Count of Participants)
	Worse	Unchanged	Slight improvement	Moderate improvement	Marked improvement	Almost clear	Clear
Group A: Dovonex®	1	4	9	12	12	0	0
Group A: LEO 19123	2	9	12	12	3	0	0
Group B: LEO 19123	1	3	1	5	2	0	0
Group B: LEO 19123 Vehicle	0	3	7	1	1	0	0

Intervention	Participants (Count of Participants)
	LEO 19123	No preference	Reference product
Group A	5	12	21
Group B	6	3	3